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The rapid advancement of medical technology has resulted in significant advantages for 
persons throughout the world. Genetic testing is an example of such advancement that has 
revolutionized medical science. However, it has also created several legal and ethical 
implications, many of which stem from the issue of confidentiality. There is unequivocally 
the need for such testing and thus there has been an almost seamless incorporation of human 
genetic technology into our healthcare system. The ramifications of such testing, however, 
have not been dealt with sufficiently by the South African legislature as well as South 
African hospitals in terms of their institutional ethics policies.      
During the genetic testing process itself, an individual may be diagnosed with a specific 
genetic condition or disorder.1 The information gained from such testing is used to prevent 
the onset of the condition.2 It may also assist persons in making decisions on the treatment 
and management of the condition.3 This information may be known as genetic information.4 
It must be stated, however, that genetic testing is not just an individual experience.5 Unlike 
other medical tests, there is a familial nature to genetic tests in that it may produce 
information that is relevant to a patient's family. Genetic tests may indicate that biological 
relatives of the individual being tested are also at risk of a genetic condition or disorder.6 
Unwittingly, this places a clinician in a difficult legal and ethical predicament.  
As a result, this study focuses on the privacy of genetic information in the context of an 
involuntary disclosure made by a medical practitioner to affected related third parties. In most 
cases, patients willingly warn affected individuals. The focal point of this study, however, 
                                                          
1 B Godard...et al 'Genetic information and testing in insurance and employment: technical, social and ethical 
issues' (2003) 11 (2) European Journal of Human Genetics 123.  
2 ibid 123. 
3 ibid 123. 
4 ‘Genetic Information Discrimination’ available at http://www.eeoc.gov/laws/types/genetic.cfm, accessed on 10 
July 2014. 
5 M Van Riper 'Genetic Testing and the Family' (2005) 50 (3)  Journal of Midwifery & Women's Health  227. 
6 S M Wolf & J P Kahn 'Genetic Testing and the Future of Disability Insurance: Ethics, Law & Policy' (2007) 
35 (2) Journal of Law, Medicine & Ethics 9. 
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occurs when a patient refuses to provide their consent to the healthcare professional, 
preventing the healthcare professional from making the disclosure. Specifically, where 
healthcare professionals are placed in the unfortunate position of having to balance a patient's 
right to confidentiality, regarding their genetic information, against a duty to warn at-risk 
relatives. This dissertation questions whether or not healthcare practitioners have a duty to 
protect their patient’s privacy at all costs.  
Moreover, this study seeks to identify and scrutinize problems related to the confidentiality 
and disclosure of genetic information. The study will go on to provide solutions in order to 
minimise such problems between a patient, a medical practitioner and at-risk family 
members. In order to fully comprehend the dilemma that healthcare practitioners are faced 
with, the scope of the doctor-patient relationship must also be examined. It is important to 
establish whether or not healthcare professionals have an obligation to abide by their duty of 
confidentiality by not disclosing genetic information they have learnt as a result of carrying 
out their professional duties.  
Furthermore, in order to understand the protection afforded to genetic information it is 
necessary to determine how genetic information is classified in South Africa. The two distinct 
views on how genetic information may be classified will be discussed later on. The manner in 
which genetic information is defined and classified in South Africa is crucial as it will 
determine how and to what degree genetic information is protected.  
Although the above questions are of extreme importance, the ultimate purpose of this study is 
to question and accordingly establish whether or not South Africa has failed to adequately 
regulate the confidentiality and disclosure of genetic information. Any lack of guidance in 
this area would be disconcerting as healthcare professionals would be left to their own 
discretion when making decisions that may affect the health of several individuals. 
Consequently, if South African regulations and guidelines are found to be deficient, this 
study aims to provide recommendations that address the legal and ethical concerns of 
healthcare professionals.   
At this juncture, it must be stated that any regulations relating to genetic information cannot 
merely be based on a legal outlook. An ethical perspective is required. Law often embodies 
the principles of ethics, and this dilemma deserves no less. There are several bioethics 
theories and biomedical ethics principles that will guide us as to what the best course of 
action is when faced with genetic information. It is my recommendation that a medical 
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practitioner must have regard for the ethical considerations involved in genetic testing before 
deciding whether or not to disclose genetic information to at-risk relatives.  
Overall, the complexities involved in genetic sciences have affected countries across the 
world, which in turn has encouraged many countries to develop guidelines that govern the 
protection and disclosure of genetic information. It is apparent that the disclosure of genetic 
information is going to become an increasingly problematic issue in South Africa, unless 
steps are taken to provide unambiguous and ethically informed legislation and ethics policies. 
Accordingly, a detailed analysis on the different approaches countries have taken when 
regulating the involuntary disclosure and protection of genetic information must be discussed. 
It is vital that we draw on foreign and international governance documents in order to provide 
well informed recommendations for future genetics legislation and organizational ethics 
policies.        
 
1.2 Breakdown of Chapters         
Chapter 2 - provides an understanding of the science involved in the study of genetics. The 
chapter goes on to examine the history and development of genetic testing. 
Chapter 3 - examines the classification of genetic information in South Africa; that is, 
whether or not genetic information falls within the definition of health information or 
whether such information is considered to be exceptional information.  
Chapter 4 - is a general examination of confidentiality and disclosure in South Africa.  
Chapter 5 - analyses current South African governance documents on the confidentiality and 
disclosure of genetic information 
Chapter 6 - involves the discussion and application of ethical theories and biomedical 
principles to the act of involuntary disclosure. 
Chapter 7 - examines foreign and international governance documents that have provided 
guidance on the confidentiality and disclosure of genetic information. It also examines the 
foreign ambit of the duty to warn.   
Chapter 8 - provides recommendations for future genetics privacy legislation and 
organisational ethics policies in South Africa.  
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The Science of Genetics: An Introduction to Genetic Testing 
 
2.1 Introduction  
With serious health related illnesses in South Africa requiring valuable resources and 
awareness, it is easy to overlook genetic conditions.7 Nevertheless, approximately 5% of all 
pregnancies result in a child being born with a serious genetic condition, disability or 
congenital malformation.8 It is also estimated that 1 in 19 South Africans have a genetic 
disorder.9 Essentially, it is important to keep in mind that a genetic condition can occur in any 
person in any country.10 This study attempts to demonstrate that with the prevalence of 
genetic conditions and genetic testing technology, issues of disclosure and confidentiality are 
bound to increase.   
Consequently, in order to fully comprehend the difficulties linked to the disclosure of genetic 
information, it is necessary to understand the science behind genetics. Understanding the 
complexities of the field of genetics will provide insight as to how these complexities can be 
solved competently with the development of adequate regulations. Accordingly, this chapter 
sets out the science of genetics as well as the history and development of genetic testing. 
 
2.2 Understanding Genetics 
2.2.1 Cells, DNA and Genes 
The human body is comprised of trillions of cells that contain hereditary material.11 A cell is 
made up of several components, but of particular importance is the nucleus which contains 
deoxyribonucleic acid (DNA), a cell's hereditary material. A nucleus contains 23 pairs of 
                                                          
7 World Health Organization 'Review of Ethical Issues in Medical Genetics' (2003) 1. 
8 ibid 1. 
9 F Loubser...et al 'Support for Genetic Counselling services in the Western Cape' (25 February 2013)  available 
at https://gcnewssa.wordpress.com/, accessed on 29 December 2014. 
10 World Health Organization 'Review of Ethical Issues in Medical Genetics' (2003) 3. 
11 'Handbook Help Me Understand Genetics' (7 July 2014) available at http://ghr.nlm.nih.gov/handbook.pdf, 
accessed on 14 July 2014.  
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chromosomes which is made up of DNA. A gene is made up of DNA and may be described 
as a functional unit of heredity. It has been estimated that a human being has between 20,000 
and 25,000 genes. Each person has two copies of each gene which are essentially inherited 
from each parent (one copy from each parent). A map is used to determine a particular gene's 
location on a chromosome.12   
 
2.2.2 Gene Mutations 
'A gene mutation is a permanent change in the DNA sequence that makes up a gene'.13 
However, not all genetic mutations cause genetic disorders. There are two ways in which a 
gene mutation may occur. Firstly, there is the acquired mutation which occurs in DNA at 
some point in an individual's life. This mutation may be caused by environmental factors (e.g. 
ultraviolet radiation from the sun) or can occur as a result of a mistake made during cell 
division when DNA copies itself. An acquired mutation cannot be inherited. Secondly, a 
mutation may be inherited from a parent. In this instance, a gene mutation may result in a 
particular condition that affects multiple members of a family.14 
 
2.2.3 Inheritance of Genetic Disorders  
Even though a genetic condition may run in a family, it is difficult to predict that a family 
member will inherit the disorder as there are several factors that influence the chances of 
developing the disorder.15 For instance, there are several ways in which the disorder may be 
inherited, the most relevant being the following:16      
   
(i) Dominant Inheritance: Where an individual has a dominant disorder, the child has a 
50 percent chance that he or she will inherit the mutated gene. 








(ii) Recessive Inheritance: Where there are 'two unaffected people who each carry one 
copy of the mutated gene for'17 a recessive disorder (carriers), the child has a 25 
percent chance of developing the disorder. 
(iii) X-linked Dominant Inheritance: Where a man has an X and a Y chromosome, a 
woman has two X chromosomes. Where a man has an X- linked dominant 
condition, his sons will not be affected, but all of his daughters will inherit the 
disorder. Where a woman has an X-linked dominant condition, there is a 50 
percent chance that her child will inherit the condition. 
(iv) X-linked Recessive Inheritance: Where a man has an X-linked recessive condition, 
his sons will remain unaffected, but 'his daughters will carry one copy of the 
mutated gene'.18 Where a woman has an X-linked recessive condition, she 'has a 
50 percent chance of having sons who are affected and a 50 percent chance of 
having daughters who carry one copy of the mutated gene'.19  
 
2.2.4 Reduced Penetrance  
When a person experiences the mutation of a particular gene and exhibits symptoms of a 
genetic condition, it is known as penetrance. Reduced penetrance occurs where a person has 
the mutation, but does not develop symptoms of the condition. For example, a person with 
the BRCA1 or BRCA2 gene mutation may or may not develop cancer during their life. A 
doctor is unable to predict if the individual with the mutation will eventually develop 
cancer.20 This example demonstrates one of the complications a medical practitioner must 
consider when deciding whether or not they should make the disclosure.  
 
 







2.2.5 Genetic Conditions 
Research has shown that the majority of conditions have a genetic element.21 As individuals, 
we have a tendency of identifying genetic disorders such as Down Syndrome, breast cancer 
and cystic fibrosis, as its own illness, forgetting that they all share a common genetic 
component. The following are examples of well-known detectable genetic conditions: 
(i) Colon Cancer: Affects both men and women and occurs when a malignant (cancerous) 
tumour develops in the large intestine. Most colon cancer cases are as a result of a genetic 
mutation that may happen to an individual. However, there is also a hereditary form, in 
which, a child may inherit the mutation from their parent.22   
(ii) Huntington's Disease: This is an inherited neurological condition that ensures the loss of 
motor control, emotional problems and cognitive decline. The gene that causes Huntington's 
disease is a dominant gene and thus if an affected individual was to have a child, there is a 50 
percent chance that the child will inherit the gene. If a child does, in fact, inherit the 
Huntington's disease gene, they will develop the disorder during their lifetime. However, if 
the child does not inherit the gene, the child will not develop Huntington's disease, nor will 
he or she pass on the gene to future children.23  
 
2.3 Genetic Testing 
2.3.1 The History and Development of Genetic Testing 
The origins of genetic testing can be traced back to the nineteenth century when Gregor 
Mendel's experiment with peas introduced the basic mechanisms of inheritance to the 
world.24 It was in 1953, however, when James Watson and Francis Crick made a discovery 
that revolutionised genetic science. In their well-known paper, Watson and Crick put forward 
an entirely different structure of deoxyribose nucleic acid (DNA) which has come to be 
                                                          
21 ibid. 
22 'Learning About Colon Cancer' available at http://www.genome.gov/10000466, accessed on 21 August 2014. 
23 'Learning About Huntington's Disease' available at https://www.genome.gov/10001215, accessed on 22 
August 2014. 
24 T H Morgan...et al The Mechanism of Mendelian Hereditary (1915) 1. 
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known as the double helix of DNA.25 Their discovery has made a profound impression on the 
development of genetics by providing great insight on gene function.26    
The 1980s saw the ideological origin for the Human Genome Project (HGP).27 The HGP set 
out an expansive research effort to sequence and map all of the genes, collectively known as 
a genome, in the human species.28 In 2000, the HGP announced that the majority of the 
human genome had been sequenced and in 2003 the project was completed, giving us the 
ability to understand the complete genetic blueprint of a human being.29 Overall, the HGP has 
uncovered an abundance of information that has allowed for the development of genetic 
testing.   
The emergence of genetic sciences in South Africa started soon after Watson and Crick's 
discovery of the double helix of DNA.30 Any discussion of the history of genetics in South 
Africa, however, would not be complete without an examination of the eugenics movement. 
The term eugenics was coined by Francis Galton in 1883.31 Eugenics advocated for the 
improvement of the human race by eliminating undesirable traits and multiplying desirable 
traits.32    
Galton's campaign to improve the human race, or at the very least prevent its' supposed 
decline through selective breeding, spread rapidly throughout the world.33 The progress of the 
eugenics movement, however, declined after the movement had been embraced by the 
Nazis.34      
In a broader context, it may be said that human genetics stems from the idea of eugenics 
which advocates for the improvement of the physical, mental and behavioural characteristics 
of a human being by means of hereditary manipulation.35 The fundamental similarity between 
genetics in the contemporary world and eugenics can be seen in one common goal: the 
                                                          
25 F Crick & J Watson 'Molecular Structure of Nucleic Acids: a Structure for Deoxyribose Nucleic Acid' (1953) 
171(4356) Nature 737. 
26 E Mayr The Growth of Biological Thought: Diversity, Education, and Inheritence (1982) 824. 
27 'A Brief History of the Human Genome Project' available at http://www.genome.gov/12011239, accessed on 
21 August 2013. The genome project was established in 1987 with the original goal of seeking information of 
gene mutations. 
28 ibid.  
29 ibid.  
30 J G R Kromberg & A Krause 'Human Genetics in Johannesburg, South Africa: Past, Present and Future' 
(2013) 103 (12) SAMJ   957. 
31 World Health Organization 'Review of Ethical Issues in Medical Genetics' (2003) 10. 
32 D J Kevles 'Eugenics and human  rights' (1999) 319 (7207) BMJ  435. 
33 D Wikler 'Can we Learn from Eugenics?' (1999) 25 (2) Journal of Medical Ethics 183. 
34 ibid 183. 
35 D J Kevles In the Name of Eugenics: Genetics and the Uses of Human Hereditary (1985) vii (preface). 
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elimination of 'inferior' genes in human beings.36 Accordingly, we can see how far the 
medical world has come as a discussion of inferior genes today would involve the elimination 
of mutated or altered genes that may be connected to a particular condition or disease.37   
From a South African perspective, eugenic ideas always seemed to be intrinsically linked to 
race.38 The eugenics movement found great momentum in South Africa in 1920 when H B 
Fantham set up the Eugenics and Genetic Standing Committee of the South African 
Association for the Advancement of Science.39 The Committee was against the mixing of 
racial groups as well as mixing between persons of the same racial groups who had different 
potentialities.40 Accordingly, appropriate marriage and sterilization laws were to be used in 
order to prevent the birth of persons suffering from hereditary mental diseases, alcoholism 
and criminal tendencies.41 The South African government, however, did not respond to the 
recommendations of the Committee and only went as far as suggesting voluntary 
sterilization.42 In the coming years, it became apparent that certain sectors of the South 
African population did not provide support for the eugenics movement.43   
More importantly, however, was the continued development of genetic services during this 
period. In the early 1960s, there was the establishment of informal genetic counselling 
services in both Johannesburg and Cape Town.44 In 1972, Trefor Jenkins, Professor of 
Human Genetics at the University of Witwatersrand, attended the International Congress of 
Human Genetics in Vienna.45 The knowledge he had gained on that trip led to the 
formalization and expansion of genetic counselling clinics in South Africa.46 1977 saw the 
growth and expansion of laboratory services and health personnel across the country.47 This 
                                                          
36 J Caplan & J Torpey Documenting Individual Identity: The Development of State Practices in the Modern 
World (2001) 280. 
37 ibid 280. 
38 S Dubow 'South Africa: Paradoxes In The Place Of Race' in A Bashford & P Levine (ed) The Oxford 
Handbook of the History of Eugenics (2010) 274. However, the apartheid regime in South African history alone 
allowed for white supremacy and thus such eugenic ideas were never of key importance. 
39 T Jenkins 'Medical Genetics in South Africa' (1990) 27 (12) Med Genet 762. 
40 ibid 762. 
41 ibid 762. 
42 ibid 762. 
43 ibid 762. 
44 J G R Kromberg & A Krause 'Human Genetics in Johannesburg, South Africa: Past, Present and Future' 
(2013) 103 (12) SAMJ   957. 
45 ibid 957. 
46 ibid 957. 
47 J G R Kromberg & E B Sizer & A L Christianson 'Genetic services and testing in South Africa' (2013) 4 (3) 
Journal of Community Genetics 416. 
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was as a result of the Minister of Health stating that genetic services formed a crucial part of 
South Africa’s health system.48  
At present, there are 12 main laboratories in South Africa that perform genetic tests.49 There 
are also various other private laboratories throughout the country where certain genetic tests 
can be performed.50 An example of such a private laboratory is Lancet Laboratories in 
Johannesburg which performed 3,292 genetic tests in 2008 alone.51 Another example that 
shows the extent of genetic testing in South Africa concerns the four academic Human 
Genetics departments who performed 16,073 genetic tests in 2008.52 
 
2.3.2 The Science of Genetic Testing 
Genetic testing refers to the study of a person's genetic make-up53 in order to establish 
whether or not that person has a genetic condition. The testing provides medical practitioners 
with the means to diagnose a genetic disorder. Genetic testing technology is currently able to 
detect numerous genetic conditions.54 There are several different types of genetic tests that 
may be used to detect and confirm a genetic disorder. These tests may also determine the 
likelihood of an individual developing such a genetic disorder or the chances of them passing 
it on to potential children. Genetic testing may provide certainty where there are suggestions 
of possible conditions, diseases or disorders in a family's medical history.55 The different 
types of genetic tests include:56 
a) Newborn Screening - involves the screening of newborns for genetic disorders which 
enables medical practitioners to treat them as soon as possible. 
                                                          
48 ibid 416. 
49 ibid 418. 
50 ibid 418. 
51 ibid 418. 
52 ibid 418. 
53 'Issues in the Insurance and Employment Settings: A Report ' available at 
https://www.law.utoronto.ca/documents/Lemmens/Genetic%20Information%20and%20the%20Law.pdf , 
accessed on  02 July 2014.  
54 'Handbook Help Me Understand Genetics' (7 July 2014) available at http://ghr.nlm.nih.gov/handbook.pdf, 
accessed on 14 July 2014.  
55 Wolf (note 6 above; 8). 
56 'Handbook Help Me Understand Genetics' (7 July 2014) available at http://ghr.nlm.nih.gov/handbook.pdf, 
accessed on 14 July 2014.  
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b) Diagnostic Testing - is performed at anytime during an individual's life in order to 
determine and ultimately confirm the presence of a particular genetic condition. This 
information will allow individuals to make decisions concerning the treatment and 
management of the condition. 
c) Carrier Testing - involves testing persons with a family history of a genetic disorder. This 
testing is used to determine the likelihood of a couple 'having a child with a genetic 
condition'.57  
d) Prenatal Testing - is used during pregnancy to determine if there is likelihood that the 
foetus will have a genetic condition.  
e) Preimplantation Testing - is used to detect genetic abnormalities in an embryo before it is 
implanted through the process of in-vitro fertilization. 
f) Predictive and Presymptomatic Testing - is testing that is used to identify gene mutations 
and accordingly the likelihood of an individual developing a genetic disorder in the future, 
that is, before there are actual signs of the disorder.       
 
2.3.3 The Imperfect Science of Genetic Testing 
Despite its predictive value, there is no denying that genetic testing still has a long way to go. 
For instance, although genetic testing is able to detect multiple genetic conditions, there are 
still genetic disorders for which no test has been developed in that the genetic cause of the 
disorder has not been found or a test to detect the condition has not been formed as yet.58 In 
terms of conditions that they do have tests for, it is important to note that such tests do not 
provide certainty. These tests generally infer that there is a likelihood that the individual will 
develop the condition.59 In these cases, genetic testing is said to be limiting.  
There are also concerns relating to the practicalities involved in genetic testing, especially in 
a developing country such as South Africa. At present, it is evident that genetic testing is only 
available at a tertiary care level and thus such services are only available at private 
                                                          
57 ibid. 
58 'Handbook Help Me Understand Genetics' (7 July 2014) available at http://ghr.nlm.nih.gov/handbook.pdf, 
accessed on 14 July 2014.  
59 B Kuschke 'Access to genetic information and the insurer's duty of genetic data protection'  (2007) available at 




practices.60 It is estimated that genetic tests in South Africa cost between R1,500 and 
R13,400 per test, depending on the specific type of genetic test required.61 The exclusivity of 
the testing ensures that average South Africans will not be able to afford genetic testing. 
Accordingly, any legislation that is implemented in the future would focus primarily on the 
private sector.  
Lastly, there are also problems surrounding the technicalities involved in genetic testing. As 
with any medical procedure, there is always the chance of an error occurring. In terms of 
genetic testing, errors in laboratories are not unheard off.62 For example, a mistake may be 
made when a sample is being taken, labeled or examined. Other problems include the 
inadequate training of personnel, inappropriate test selection and misinterpreting test 
results.63  In terms of these inadequacies, it is clear that future genetics legislation should also 
contain guidelines on good laboratory and testing practices.        
 
2.4 Conclusion 
Although genetic testing has come a long way, it is apparent that the study of genetics is not 
based on complete accuracy. Where genetic testing produces indecisive results, it would seem 
that medical practitioners would go through a much more difficult thought process when 
deciding whether an involuntary disclosure needs to be made. Accordingly, it is submitted 
that the lack of certainty involved in genetic testing justifies the need for exclusive genetics 
legislation that takes the uncertainty of genetics into account. 
    
                                                          
60Kromberg (note 47 above; 416). 
61 M C Herbst 'Fact Sheet on Genetic Testing for Cancer' (June 2014) available at 
http://www.cansa.org.za/files/2014/06/Fact-Sheet-Genetic-Testing-Cancer-June-2014.pdf, accessed on 15 
December 2014. 
62 D Ravine & G Suthers 'Quality standards and samples in genetic testing' (2012) 65 (5)  Journal of Clinical 
Pathology 1. 
63 'Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions' , available 
at http://www.sashg.org/documents/CDC%20guidelines%20for%20genetic%20testing%20June%202009.pdf, 








In order to determine the extent and ambit of the protection afforded to genetic information, it 
is necessary to establish how genetic information is defined and accordingly classified. The 
classification of genetic information is a controversial topic that has been debated throughout 
the world, resulting in two distinct schools of thought. Firstly, genetic information may be 
recognized as health information. On the other hand, we can recognise the uniqueness of 
genetic information and accordingly classify such information as distinctive from standard 
health information.64 A determination is essential as such a classification will determine if 
special protection is required for such sensitive information. 
 
3.2 The Definition of Genetic Information         
In the United States, the Genetic Information Nondiscrimination Act (GINA) has defined 
genetic information as:65 
(4) Genetic information-- 
(A) In general -- The term “genetic information” means, with respect to any 
individual, information about-- 
(i) such individual’s genetic tests, 
(ii) the genetic tests of family members of such individual, and 
(iii) the manifestation of a disease or disorder in family members of such individual. 
                                                          
64 L O Gostin & J G Hodge 'Genetic privacy and the law: An end to genetics exceptionalism' (1999) 40 
Jurimetrics 31. 
65 The Genetic Information Nondiscrimination Act of 2008 section 201. 
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(B) Inclusion of genetic services and participation in genetic research.--Such term 
includes, with respect to any individual, any request for, or receipt of, genetic 
services, or participation in clinical research which includes genetic services, by such 
individual or any family member of such individual. 
(C) Exclusions -- The term “genetic information” shall not include information about 
the sex or age of any individual. 
In 2010, final regulations were added under GINA which expanded the definition of genetic 
information to include information of the foetus carried by the individual as well as 
information on the individual's relative who is pregnant. The regulation goes on to state that 
genetic information also includes information on an embryo that is legally held by the 
individual or their relatives.66 
Although broad, GINA has provided a comprehensive definition of genetic information. 
From this definition, we can state that genetic information includes information on the 
genetic tests of not only the relevant individual, but also their family members. It is also 
impressive that GINA goes further with its regulations by including information on future 
and potential children. For the purposes of this study, we can accept the extensive definition 
provided by GINA. 
 
3.3 Health Information verses Genetic Exceptionalism 
3.3.1 Health Information 
From the above definition, the composition of genetic information is reasonably clear. 
However, the ultimate question asked by academics is whether or not genetic information is, 
in fact, special when compared to health information. Ethicist, Thomas Murray, contends that 
there is no justifiable reason for treating genetic information differently from other health 
information.67 Dr Murray asserts that an acceptance for exceptionalism would result in a clear 
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divide of diseases and disorders into separate groupings: genetic and non-genetic illness.68 In 
support of this argument he has stated that there is not much in terms of our health that has no 
genetic element.69 Dr Murray has gone on to state that much of our medical information is, in 
fact, genetic information, but is not defined as such because it is not as a direct result of a 
genetic test. 70 
Undeniably, there is merit in his argument as it is virtually impossible to completely separate 
health and genetic information. However, stating that genetic information should receive the 
same amount of protection as health information simply because there are similarities 
between the two should not be a compelling enough argument. In this instance, it is important 
to remember the exceptional information that can be derived solely from genetic tests.  
Other writers that are against exceptionalism include Gostin and Hodge who have concluded 
that genetic exceptionalism is flawed for two reasons:71 
(i) strict protections of autonomy, privacy and equal treatment of persons with genetic 
conditions threaten the accomplishment of public goods; and  
(ii) there is no clear demarcation separating genetic data from other health data; other 
health data deserve protections in a national health information infrastructure. 
Additionally, we may question the exceptionalism of genetic information as it may be 
relegated to just another means that is used to establish a medical condition.72 In fact, it has 
been stated that certain medical tests provide more certainty than genetic testing.73 A 
cholesterol test, for example, may predict and confirm poor health, whereas genetic testing, in 
certain cases, may only provide knowledge on increased susceptibility to a particular 
condition.74 From the definition of genetic information provided by GINA, we can state that 
genetic information does not include any specific medical information, that is, the definition 
focuses on information that is as a result of genetic testing. Accordingly, in line with this 
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school of thought, it may be said that genetic information is not always as exceptional as one 
might believe.  
 
3.3.2 Genetic Exceptionalism 
In terms of genetic exceptionalism, genetic information is regarded as unique information, 
separate from standard health information.75 Genetic exceptionalism has been defined as the 
'societal practice of treating genetic data as different from other types of health data for the 
purposes of assessing privacy and security protections'.76 Proponents of genetic 
exceptionalism, Annas, Glantz, and Roche state that there are three reasons as to why genetic 
information should be considered as distinctive private information:77     
(i) it can predict an individual's likely medical future for a variety of conditions; 
(ii) it divulges personal information about one's parents, siblings and children; and  
(iii) it has historically been used to stigmatize and victimize individuals.    
As noted above, genetic information may include information on genetic disorders that 
individuals may have already developed. However, such information is also of a predictive 
nature as it determines the likelihood of the individual actually developing the genetic 
condition.78 In addition, genetic information may also be used to prevent genetic conditions 
that, at present, cannot be cured.79 Genetic information also has the potential to influence 
individuals’ decisions on reproduction, health and lifestyle.80  
Another facet that sets genetic information apart is the fact that genetic tests produce 
information on whether or not the individual's family is at risk of certain genetic disorders.81 
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By itself, this aspect is certainly exceptional as the affected family members may not have 
had this information previous to the testing of the individual.82.    
Overall, writers have also argued that genetic information is special, as where the gene is 
hereditary and not acquired, it provides information that is not dependent on a person's 
personal decisions surrounding their diets and lifestyle.83 It is apparent that genetic testing 
can produce information that no other scientific testing can provide. The impact that this 
information can have on at-risk relatives, in my opinion, justifies why genetic information 
should be treated as exceptional. Accordingly, it is submitted that such distinct and sensitive 
information deserves a higher degree of protection than standard health information.       
 
3.4 Conclusion 
Overall, academics throughout the world continue to debate for and against genetic 
exceptionalism. Undoubtedly, genetic and health information, to a certain extent, is and will 
always be intrinsically linked. However, from the above discussion, it is clear that genetic 
testing produces information that is different from health information Therefore, it is 
submitted that in order to prevent the mismanagement of genetic information, there is a need 
to develop exclusive regulations that provide specific guidance on how to handle genetic 
information. For this reason, this study proposes that for the purposes of special protection, 
there is a need to lean towards genetic exceptionalism.  
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Medical practitioners are placed in a difficult position when they obtain knowledge, through 
their patient, that is helpful to third parties. In these situations, clinicians have the 
burdensome task of having to decide whether or not to breach confidentiality. Accordingly, 
this chapter examines the ambit of confidentiality and privacy laws in South Africa. It goes 
on to explore disclosure laws in South Africa and whether or not these laws apply to genetic 
information.  
 
4.2 The Ethical Duty of Confidentiality 
The trust and confidentiality involved in a doctor-patient relationship is not based purely on 
the law. There is an ethical duty that a medical professional has towards their patient. There 
are several sources of ethical codes in terms of confidentiality. For instance, there is the age-
old Hippocratic Oath which is at the cornerstone of the ethical duty to maintain 
confidentiality in a doctor-patient relationship.84 There is one section of the Oath that is of 
particular importance when discussing the concept of confidentiality:85 
Whatsoever things I see or hear concerning the life of men, in my attendance on the 
sick or even apart therefrom, which ought not be noised abroad, I will keep silence 
thereon, counting such things to be as sacred secrets. 
The above words contained in the Hippocratic Oath captures the essence of the concept of 
confidentiality. This statement alone demonstrates the abundance of respect afforded to the 
principle of confidentiality. In order to emphasize the importance of the Hippocratic Oath, it 
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must be mentioned that the World Medical Association (WMA) has updated the Oath in 1948 
which has resulted in the Declaration of Geneva.86 
The ethical principle of autonomy also plays a vital role in the confidentiality of a doctor-
patient relationship.87 In terms of this principle, personal information of an individual belongs 
to that individual and should not be disclosed to others, unless consent is obtained or in the 
instance 'where there is a legitimate requirement to breach confidentiality'.88 Patients have an 
expectation of privacy when they share personal information with their medical practitioner, 
and thus in terms of their right to privacy,89 they should be allowed autonomy over their 
private information.90 
There is also the concept of trust to consider. A patient's expectation of confidence allows for 
trust which in turn ensures communication during the diagnosis and treatment process. Trust 
between a doctor and their patient ensures an openness and willingness from the patient to 
communicate. Where there is no understanding that a doctor has an ethical and legal duty to 
maintain the confidences of a patient, the doctor-patient relationship becomes inconsequential 
as in all probability, patients would withhold information that is necessary to make a correct 
diagnosis.91  
Furthermore, in the event that a breach of confidentiality is justifiable, good clinical practice 
will dictate that patients should be advised before rather than later that their confidential 
information has been disclosed.92 Even where the disclosure is necessary and justifiable, 
when a healthcare practitioner breaches confidentiality, they should be aware that they are 
likely going to lose the trust of a patient, irreversibly harming the doctor-patient 
relationship.93 Accordingly, it must be mentioned that the HPCSA has predicted such harm to 
the doctor-patient relationship and has thus developed guidelines94 which examines the 
concept of consent to testing. These guidelines state that there is only informed consent 
where healthcare practitioners have discussed certain matters with anyone considering 
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genetic testing.95 This will include a discussion on the possibility of disclosure to affected 
related third parties. Essentially, it is hoped that the honesty provided by healthcare 
practitioners is sufficient to maintain a healthy doctor-patient relationship.  
 
4.3 Confidentiality Laws in South Africa  
Privacy and confidentiality laws in South Africa are currently governed by the Constitution,96 
legislation, and the common law. At the core of statutory law is the National Health Act97 
(NHA) which is arguably the most important and comprehensive health legislation that the 
South African legislature has ever passed. The NHA provides guidance and certainty on a 
variety of complex health issues relevant in South Africa. Of particular importance to this 
study, is the section on confidentiality. This section essentially recognizes and protects the 
confidentiality of health information.98 Section 14 of the NHA regulates confidentiality 
between a healthcare professional and their patient. The section reads as follows:99 
 (1) All information concerning a user, including information relating to his or her 
health status, treatment or stay in a health establishment, is confidential. 
(2) Subject to section 15, no person may disclose any information contemplated in 
subsection (1) unless- 
(a)   the user consents to that disclosure in writing; 
(b)   a court order or any law requires that disclosure; or 
(c)   non-disclosure of the information represents a serious threat to public health. 
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4.3.1 Confidentiality, Disclosure, and Genetic Information 
Section 14 of the NHA100 makes health information confidential and thus in order for genetic 
information to be confidential under the NHA it must fall under the classification of health 
information. Hypothetically, if genetic information were to be classified as health 
information, genetic information would remain confidential between a patient and their 
doctor, unless one of the above three exceptions applied. In the event that one of the above 
exceptions do not apply, the information remains confidential, unless the healthcare provider 
decides to involuntarily disclose such information. It is important to remember, however, that 
there is no indication from the NHA that genetic information does, in fact, fall under the 
scope of the Act.    
Accordingly, section 15 of the NHA101 regulates disclosures made by a healthcare 
provider:102   
(1) A health worker or any health care provider that has access to the health records of 
a user may disclose such personal information to any other person, health care 
provider or health establishment as is necessary for any legitimate purpose within the 
ordinary course and scope of his or her duties where such access or disclosure is in the 
interests of the user. 
In terms of this section, a healthcare provider may only make a disclosure if it is in the 
interests of their patient.103 However, this dissertation deals with the situation in which a 
medical practitioner makes a disclosure for the benefit of a third party. Accordingly, when a 
medical practitioner makes such a disclosure, it is apparent that it is against the wishes of 
their patient and thus contrary to section 15(1) of the NHA104, that is, the disclosure is not in 
the interest of the patient. As a result, we can conclude that section 15(1) of the NHA105 does 
not regulate the involuntary disclosure of genetic information.  
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Accordingly, this dissertation sets out to determine whether the NHA106 should be amended 
to unambiguously include guidance on the protection and involuntary disclosure of genetic 
information. This would ensure the confidentiality of genetic information. Alternatively, 
Parliament could create legislation that focuses exclusively on genetic information and its 
implications.  
At this juncture, it is important to emphasize that this study is proposing that genetic 
exceptionalism should be accepted in South Africa. In line with this proposition, genetic 
information should have its own classification, rather than being classified as health 
information. This study asserts that genetic information is unique and distinctive information 
that warrants special protection. For this reason, in line with the concept of genetic 
exceptionalism (discussed in the previous chapter), this study proposes the need for exclusive 
legislation that will adequately regulate the confidentiality and involuntary disclosure of 
genetic information.      
In support of this assertion, the Promotion of Access to Information Act107 must be 
mentioned. Essentially, in terms of genetic information, it is apparent that this Act cannot 
provide relief for affected third parties in that a third party may only call upon this right if 
they are aware that there is genetic information relevant to them. Accordingly, this 
dissertation focuses on the instance where affected third parties are unaware that there is, in 
fact, information that is of interest to them. As a result, the right provided in the Promotion of 
Access to Information Act108 is insufficient and thus exclusive effective genetics legislation is 
required.  
   
4.3.2 Protection of Personal Information Act  
In 2013, the president signed the Protection of Personal Information Act109 (POPI). However, 
as of 11 April 2014 only certain sections of POPI have come into force.110 POPI is relevant to 
this study in terms of section 32(5) of the Act which states that 'Personal information 
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concerning inherited characteristics may not be processed in respect of a data subject from 
whom the information concerned has been obtained...' 
In this study, it is submitted that the NHA111 deals exclusively with health information (which 
does not include genetic information). One of the reasons for this conclusion is that S32(51) 
of POPI specifically uses the words inherited characteristics. The use of such terminology 
infers a distinction between genetic information and health information as recognised by the 
NHA. Although recognition of this exceptional information is a positive step, there is still the 
need for the legislature to develop legislation that adequately deals with the concept of 
genetic information.  
 
4.3.3 The Right to Privacy 
In South Africa, the right to privacy is both a Constitutional and a common law right. The 
right to privacy is a fundamental right in our Constitution that all South African's are entitled 
too.112 The concepts of privacy and confidentiality are intrinsically linked to one another. The 
concept of privacy, however, is clearly distinctive as it 'relates to aspects of a person's being 
into which no one else should intrude'.113 Privacy is clearly a bigger notion than 
confidentiality and thus problems may arise when attempting to establish the ambit and scope 
of the right to privacy.  
The right to confidentiality appears indirectly in section 14 of the Constitution in terms of the 
right to privacy, which states the following:114 
Everyone has the right to privacy, which includes the right not to have: 
 a) their person or home searched; 
 b) their property searched; 
 c) their possessions seized; or 
 d) the privacy of their communications infringed. 
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The section of particular importance is s 14(d) which makes reference to the privacy of their 
communications. Ultimately, we can infer that this section protects any communication 
between the individual undergoing genetic testing and his or her medical practitioner.  
Essentially, when a patient reveals personal information to their medical practitioner, they 
make the conscious decision to surrender control of certain aspects of their privacy in the 
belief that the information will remain solely with that practitioner. Even though they have 
relinquished a limited amount of control of their privacy, he or she should still have control 
as to how that information is shared.115 Accordingly, a patient’s privacy is violated when 
personal genetic information is shared with others, against their wishes.    
It is crucial to point out that the Constitutional Court has also recognized the right to privacy 
as a common law right.116 The Constitutional Court has stated that there is an intrinsic link 
between human dignity and privacy.117 In terms of this dissertation, when a medical 
practitioner discloses a patient's genetic information to a third party, without their consent, 
the patient's privacy is violated. When such an infringement occurs, a patient's dignity118 will 
also be affected. Accordingly, when a doctor decides to make an involuntary disclosure, he or 
she needs to be aware that the patient's right to privacy is not the only right that is being 
violated.  
The common law right to privacy requires healthcare professionals to keep the confidence of 
their patients, except in certain circumstances. 119 The exception that is relevant to this study 
occurs where there is a threat to an endangered third party. A case that highlights this 
exception is the case of Tarasoff v Regents of the University of California120 which essentially 
stated that there may be a breach of confidentiality where there is an endangered third party. 
Generally, in terms of this exception, a medical practitioner has a ‘moral, social and legal 
duty to disclose certain information to an endangered third party that could save that person’s 
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life, or possibly prevent irreversible damage to his or her health’.121 On the whole, it can be 
said that the disclosure of genetic information to at-risk relatives satisfies this criteria.  
 
4.3.3.1 The Limitation Clause 
As with all rights contained in the Constitution,122 the right to privacy is not absolute. The 
right to privacy may be limited in terms of section 36 of the Constitution. Section 36(1) of the 
Constitution states that any right contained in the Bill of Rights may be limited in terms of 
the law of general application where it 'is reasonable and justifiable in an open and 
democratic society based on dignity, equality and freedom'. 123 Accordingly, even though a 
patient has a right to the privacy of their genetic information, this right may be limited where 
there is an affected related third party.  
 
4.3.3.2 Access to Information   
Section 32(1) of the Constitution124 provides that every person has the right to access 
information. The Promotion of Access to Information Act125 is national legislation that gives 
effect to the right to access information in terms of section 32(2). In terms of this Act, it is 
important to note that medical information falls under the definition of personal information. 
Accordingly, section 34(1)126 states that a public body must refuse access to a record if the 
disclosure involves the unreasonable disclosure of personal information of a third party. 
Section 34(2)(d)127 goes on to states that a record may not be refused where the information 
consists of a person's physical or mental health, or well-being. Consequently, it is apparent 
that affected related third parties should be allowed to access the genetic information of a 
relative as it concerns their health. 
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Furthermore, access to information is an important right that an affected related third party 
has. At the same time, however, the patient has a right to privacy of their genetic information. 
This conflict of rights experienced by the affected family member and the patient demand 
that a balancing of rights take place. Accordingly, the limitation clause will come into effect 
in order to establish which right takes precedence in the particular circumstances. The 
purpose of this study is not to disregard the right of privacy that all patients are entitled to and 
therefore there is the need to emphasize that the third party's right to information cannot 
consistently take preference over a patient's right to privacy. Each case must be considered 
individually.      
Moreover, despite the significance of the right to access information and, it is important that 
we criticize the effectiveness of the right in this instance. Essentially, an affected third party 
may only exercise the right if they are aware of the relevant genetic information. Where a 
patient refuses to consent to the disclosure, it seems unlikely that affected individuals would 
realise that there is information that is of interest to them. Accordingly, the right to access 
information cannot come into play if the affected party is unaware of the existence of relevant 
information, thus making this provision inadequate in terms of the disclosure of genetic 
information.  
 
4.3.4 The Privileged Relationship 
The notion of privilege also forms an important part of the doctor-patient relationship. As a 
medical professional, there is a duty to ensure the confidence of your patients, and thus, in 
South Africa, the doctor- patient relationship is a privileged one.128 However, it is important 
to note that in a doctor-patient relationship there is relative privilege, rather than absolute 
privilege which is associated with an attorney-client relationship.129 In absolute privilege, 
under no circumstances is an attorney allowed to disclose information provided by their 
client.  Relative privilege, however, refers to the situation, in which, for example, a court 
orders a medical professional, despite their refusal, to reveal confidential health 
information.130 This provides an opportunity for a medical practitioner to make a disclosure 
when it is necessary. Furthermore, qualified privilege will exist where the medical 
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practitioner making the disclosure has a 'moral, legal or social duty to make the disclosure to 
a person who has a reciprocal interest in receiving the information'.131        
 
4.3.5 Implications of Breaching Confidentiality  
Where a healthcare practitioner does, in fact, breach the confidentiality of a patient, he or she 
must be aware that the non-consensual patient has the following legal remedies:132 
(i) A civil action against the healthcare professional for the invasion of privacy or even 
defamation. 
(ii) The patient may make a complaint to the relevant regulatory body (e.g. the HPCSA). 
(iii) The healthcare processional may also receive disciplinary action where a patient lays a 
complaint with the healthcare professional's employer. 
Liability for breaching confidentiality is an important aspect. Presumably, it is on the minds 
of practitioners wanting to make a disclosure. The absence of guidance on disclosure of 
genetic information will affect the decision of the medical practitioner as he or she would 
most likely opt on the side of caution, choosing not to make the disclosure. On the other end 
of the spectrum, however, medical practitioners may feel that they will be liable for a failure 
to warn affected related third parties. Accordingly, it may be stated that the HPCSA have 
attempted to address this issue by providing guidelines that state certain circumstances in 
which a medical professional may disclose confidential information.133 Overall, however, 
medical practitioners should be free from thoughts of liability when making such a crucial 
decision and thus there is the need for legislation that tackles this issue adequately.           
 
4.4 Conclusion 
Confidentiality between a clinician and their patient is not as straightforward as it once was. 
The modern phenomenon of genetic testing has shown us this by bringing confidentiality and 
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disclosure issues to the forefront of modern medicine. In South Africa, much emphasis has 
been placed on the right to privacy and thus confidentiality. This, however, does not mean 
that patients are completely autonomous individuals. As shown above, disclosure has become 
a major part of our law. Balancing these rights, however, are not always easy for medical 
practitioners. Nevertheless, the situation should not be ignored by continuously ensuring the 




South African Governance on Genetics 
 
5.1 Introduction 
The uncertainty revolving around genetic information has left medical practitioners and 
academics scouring current South African health legislation and governance documents, 
searching for guidance on how to deal with the disclosure of genetic information. 
Accordingly, an analysis of all current regulations put forward in South Africa on this topic is 
necessary. It is important to determine whether or not South Africa lacks an adequate genetic 
sciences framework. Consequently, this chapter examines the progress that South Africa has 
already made in establishing a framework that focuses on the confidentiality and disclosure 
of genetic information.  
 
5.2 South Africa Legislation on Genetics 
5.2.1 The Human Tissue Act 
Although repealed in 2012,134 the Human Tissue Act135 was a significant piece of legislation 
that has laid down the foundation for current health legislation in South Africa. 
Unfortunately, it is apparent that such legislation did not govern genetics in any form. The 
Act does not mention the confidentiality of genetic information or any other type of health 
related information. Fortunately, with the introduction of regulations, the complete disregard 
for matters concerning genetic information is slowly coming to an end. Lastly, it must be 
mentioned that many of the provisions in the Human Tissue Act that were not included in the 
NHA have now been included in the Regulations of the NHA.  
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5.2.2 The National Health Act: Regulations 
Previously, the comprehensive provisions contained in the NHA failed to provide any 
guidance on genetics and the privacy of genetic information. This changed in The Health 
Professions Council of South Africa 2012 when regulations concerning the storage and flow 
of genetic information were passed.136 Unfortunately, there are no explicit provisions 
concerning disclosure to affected related third parties. However, the Government Gazette is 
still useful as it states that information will not be disclosed to a relevant person without the 
consent of a patient.137 In essence, information is treated as confidential and the patient has 
complete control over the use of the information. At this point, it is important to note the 
contradiction between South African regulations and guidelines.  
Essentially, while regulations state that genetic information may only be disclosed where the 
patient has provided their consent, HPCSA guidelines138  (discussed in chapter 4) seem to 
provide a more flexible approach. Although no direct reference is made to genetic testing, the 
HPCSA has outlined detailed guidance that allows clinicians to disclose personal information 
where a patient's interest is outweighed by the public interest, that is, affected related third 
parties.139 Contradictions between ethics guidelines and regulations only add confusion to an 
already complex situation. This inconsistency reinforces the need for a cohesive legislation 
that governs genetic information. Accordingly, where there is a conflict between NHA 
regulations and HPCSA guidelines, it is important to bear in mind that the regulations will 
take precedent.  
Overall, the regulations provided for in the gazette are restrictive and limiting. Unlike 
HPCSA guidelines, the regulations fail to consider that genetic information affects more than 
one individual. The recommendations made in this dissertation allows for a flexible approach 
that attempts to reach decisions that are in the best interests of all parties involved.  
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5.3 South African Guidelines 
5.3.1 The Health Professions Council of South Africa 
The Patient's Rights Charter states that information regarding a patient's health status is to 
remain confidential, unless a patient consents to the disclosure of such information.140 The 
Health Professions Council of South Africa (HPCSA) has also developed guidelines on 
confidentiality between a doctor and their patient.141 The HPCSA (Rule 13 of the Ethical 
Rules) provides that a medical practitioner may only disclose confidential information in 
certain circumstances, which includes:142  
 In terms of a Statutory provision,  
 At the instruction of a court,  
 In the public interest,  
 With the express consent of the patient,  
 Disclosures in the public interest would include but not be limited to situations where 
the patient or other persons would be prone to harm as a result of risk related contact.  
In terms of public interest, the guidelines state that where a patient refuses to consent, it is 
possible to make a disclosure in the public interest where the benefits to an individual or to 
society outweigh the patient's interest in keeping the information confidential.143 The 
guidelines specifically use an example of an endangered third party in the context of a HIV 
patient.144 It is submitted that a related third party who is affected by the genetic information 
of a patient qualifies as an endangered third party, thus making disclosure, in this instance, 
acceptable. The HPCSA guidelines go on to state that in these cases, medical professionals 
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must weigh the possible harm against the benefits likely to occur from the disclosure of 
information.145 
Furthermore, the guidelines state that the disclosure of personal information may be justified 
'where third parties are exposed to a risk so serious that it outweighs the patient's right to 
confidentiality'.146 An example of such an instance would be gaining pertinent information 
through genetic testing. Although the ethical duty of confidentiality is important, the above 
exceptions clearly indicate that such a duty is not absolute. In certain circumstances, a 
healthcare practitioner may have a duty to disclose confidential information even if it is 
contrary to the wishes of the patient. In considering such an involuntary disclosure, the 
ethical duty to society must be weighed against the ethical duty to a patient. 147 The overall 
approach taken by the HPCSA is in line with the recommendations made in this thesis. This 
study, however, wishes to take this approach further by providing a more detailed procedure 
that assists healthcare practitioners in making informed decisions.      
 
5.3.1.1 HPCSA: The Duty to Disclose and Endangered Third Parties  
The General Ethical Guidelines148 provided by the HPCSA  discuss disclosure by healthcare 
professionals. However, before a discussion on disclosure can take place, it is crucial to 
outline other relevant provisions in the HPCSA guidelines, specifically section 17 which 
examines consent to screening and testing in terms of genetics.149 The HPCSA provision 
states that in order for there to be an informed decision a healthcare practitioner must discuss 
certain factors with anyone considering genetic testing. The factor of most relevance is 
provided in 17.2.4 which states that a clinician must explain 'any significant medical, social 
or financial implications of screening or testing for the particular condition or 
predisposition'.150   
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The concept of social implications in this instance could clearly indicate the involvement of 
affected third parties. In terms of genetic testing, it can be said that these guidelines have 
made it necessary for medical practitioners to inform patients on the possibility that the 
results of their tests may affect others and that disclosure to these related third parties may be 
necessary. Due to the vagueness of the provision, however, it is difficult to say with certainty 
if, in fact, section 17 requires a medical practitioner to discuss with their patients the issue of 
disclosure to affected related third parties. Nevertheless, it may be argued that the term 
"social implications" is wide enough to encompass the possibility of disclosure to affected 
related third parties.      
Furthermore, it is important to remember that the HPCSA has also provided guidance on the 
actual duty to disclose. The guidelines contained in the General Ethical Guidelines allow 
healthcare practitioners to make disclosures when there is a compelling reason to do so.151 
For such a reason to exist, there must be 'the likelihood of serious harm to an identifiable 
third party'.152 Accordingly, in terms of these guidelines, a medical practitioner may disclose 
vital genetic information when an affected third party is vulnerable to serious harm. 
Consequently, it may be said that South Africa, to a certain extent, has recognised a duty to 
disclose. Although not as evident as some would prefer, these guidelines provide some 
guidance in terms of the duty to disclose in South Africa.   
There is also the concept of endangered third parties which is particularly relevant in the 
context of HIV infected persons. The HPCSA have provided guidelines on partner disclosure 
which state that it is good clinical practice for practitioners to encourage their HIV positive 
patients to inform their partner of their HIV status.153 In the event that a patient refuses to 
consent to the disclosure, deciding whether or not to make a disclosure is at the discretion of 
the healthcare professional.154 In this instance, the healthcare professional looks at the 
circumstances of the case.  
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Accordingly, it is important to note that HPCSA guidelines155 have allowed for disclosure to 
endangered third parties in the context of genetic research.156 This reinforces the idea that the 
concept of confidentiality in the field of genetics in South Africa is not absolute. Overall, the 
approach taken by the HPCSA is similar to the one that this dissertation advocates for in the 
context of disclosure of genetic information. If the duty to disclose can be recognised in the 
context of endangered third parties, it can similarly apply in the genetic diagnostics context in 
relation to affected related third parties.   
 
5.3.2 The Southern African Society for Human Genetics 
The Southern African Society for Human Genetics (SASHG) is an organization that cannot 
be ignored when discussing guidelines in genetics. However, despite publishing several 
documents that provide guidance in relation to the field of genetics, the interest and focus of 
SASHG has not extended as far as disclosures of genetic information. Nevertheless, SASHG 
does understand the importance of genetic counselling and has thus examined the scope of 
counselling in addition to providing the following comprehensive definition of the concept:157  
Genetic counselling is a process whereby individuals and their families are assisted in 
addressing their concerns relating to the presence of or risk of a genetic disorder in 
themselves or a family member.  
 
5.3.3 Genetic Counselling  
Genetic counselling began to gain popularity when the Human Genome Project started to 
understand the genetic causes of many disorders as well as possible preventative methods and 
treatments for these disorders.158 This study realises the importance of counselling and thus 
advocates for a non-directive approach to counselling. During non-directive counselling, a 
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patient should be offered accurate and unbiased information by a genetic counsellor who 
supports a patient throughout the decision-making process.159  
The work of a genetic counsellor includes examining a family's medical history, 
understanding and interpreting information about genetic conditions, discussing inheritance 
patterns of relevant genetic disorders, calculating risks of individuals and providing testing, 
treatment and management options to families.160 Genetic counselling helps a patient make 
adjustments to their lifestyle in order for them to cope with the genetic disorder.  In other 
words, a genetic counsellor assists a patient and their families in making informed decisions, 
which includes decisions on future reproduction.161  
As of May 2014, they were 44 genetic counsellors that were registered with the HPCSA, in 
which, 2 are student genetic counsellors, 6 are intern genetic counsellors and 10 are student 
intern genetic counsellors.162 According to mid-year statistics for 2015, the South African 
population is estimated at 54.96 million people.163 Essentially, despite the South African 
government and global health organisations expressing a need for genetic counsellors, the 
actual number of counsellors we do have is inadequate, especially considering the size of our 
population.164 The United States, for example, has a much better counsellor to patient ratio in 
that there is about 1 genetic counsellor for every 123,000 individuals.165   
From the above figures it is easy to conclude that a large population of South African's are 
not receiving the support that genetic counselling can provide. This dissertation submits that 
the field of genetic counselling remains small because of a failure to create awareness of 
genetic counsellors.   
Accordingly, Genetic Counsellors South Africa (GC-SA), a subgroup of Southern African 
Society for Human Genetics, is invaluable to the field of genetics. Their main goals include 
continuing the development of genetic counsellors; providing accessible genetic counselling 
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to all communities in South Africa and advocating for patients and their support groups.166 
Groups such as GC-SA must become essential if South Africa is ever going to embrace the 
concept of genetic counselling.           
Overall, this study recommends that counselling should be provided to a patient before he or 
she undergoes the genetic testing process. The idea behind such counselling should be to 
provide a level of comfort and knowledge to a patient who may not be adequately informed 
on the process. During this time, it would also be productive to prepare the individual for the 
possibility of a disclosure to affected related third parties.  
 
5.3.3.1 Genetic Counselling: Ethical Guidelines 
At this juncture, it is important to examine domestic ethics guidelines on genetic counselling 
that have a different stance to the regulations of the NHA. Two examples of such guidelines 
would be the recommendations produced by the Medical Research Council167 (MRC) of 
South Africa and the guidelines produced by HPCSA.168 These guidelines were developed for 
the purpose of obtaining a patient's informed consent for genetic testing. 
Firstly, section 3.3.3 of MRC guidelines recommend that certain information be given to any 
patient undergoing genetic testing. 169 This information includes the seriousness of the 
condition, treatment options for the condition, reliability of results, probability of developing 
a genetic condition, and the implications for relatives.170 The guidelines go on to state certain 
ethical principles that should be adhered to during the counselling process.171 One such 
principle states that health professionals should inform their patients that the ethical duty to 
tell affected relatives of genetic risks lies with them.172 Accordingly, it is clear that these 
guidelines focus on the individual at the expense of affected related third parties. 
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Another set of guidelines specific to the discipline of genetics are the HPCSA guidelines.173 
Although these guidelines are used for genetic testing in a research context, they may still be 
helpful in the clinical situation discussed in this study. In terms of these provisions, there is 
certain information that must be disclosed to a research participant in order for the participant 
to make an informed decision concerning the collection of genetic material and 
information.174 This includes all the details of the conditions that are discovered during the 
research as well as information that may be relevant to future offspring or relatives.175  
Furthermore, the participant must be informed that where there is research information 
relevant to the health of relatives, no disclosure will be made to these affected relatives 
without the consent of the participant.176  
Even though the HPCSA guidelines are in the context of research, it is important to 
remember that the core concepts of this study is confidentiality and disclosure, two 
problematic terms that have been identified and examined in these guidelines. Accordingly, 
we can learn how South African guidelines have dealt with these notions in the context of 
genetics. Consequently, it is apparent that these guidelines, similar to those developed by the 
MRC, prioritise confidentiality as the patient has the final decision of whether or not to 
disclose. Although placing a patient first is admirable, this approach can be rather simplistic 
in the context of a complicated situation. In contrast to the above guidelines, this study argues 
that medical professionals should inform a patient during counselling that there is, in fact, a 
chance that the disclosure will be made to affected related third parties without their consent.    
  
5.3.4 Genetics Policy Guidelines in South Africa  
In 2001, the Department of Health published Policy Guidelines for the Management and 
Prevention of Genetic Disorders, Birth Defects and Disabilities.177 These guidelines state that 
genetic information must remain confidential, except where there is a risk of serious harm to 
relatives and the information could be used to prevent such harm.178 The mention of 
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confidentiality is commendable, but there is still much to be desired in terms of disclosure. 
Firstly, there is no attempt to define "genetic information". In fact, South African guidelines 
in general have failed to provide a comprehensive definition of genetic information. In the 
absence of such a definition being spelled out in local guidelines, we may look to the 
definition provided by GINA for guidance. (Discussed in chapter 3). 
Furthermore, there are no guidelines to indicate what constitutes "serious harm". 
Accordingly, there is also no mention of counselling and disclosure-related procedures that 
healthcare professionals should adhere to. Another shortfall is that these guidelines are not 
legally binding. Overall, this dissertation submits that this document is inadequate as it fails 
to provide sufficient guidance to healthcare professionals. Nevertheless, the one positive that 
can may be taken away from these guidelines is that in the case of genetic information, the 
right to confidentiality in South Africa is not absolute.    
Another question that must be asked is how effective have these guidelines been in South 
Africa. Considering that this is the first comprehensive document that provides guidance on 
human genetics in South Africa, should there not have been the implementation of 
recommendations? For instance, the guidelines have recommended that positions for genetic 
counsellors should be made available throughout the country.179 Even though the document 
states that 320 genetic counsellors are ideally required,180 at present, there are only 26 fully 
qualified genetic counsellors that are registered with the HPCSA.181 The failure to achieve 
this goal adds to the doubt that this document is, in fact, satisfactory.   
 
5.4 Conclusion 
From the above examination of guidance documents, it is apparent that even though there are 
certain regulations in South Africa that may be applied, there are no explicit regulations that 
sufficiently manage the confidentiality and disclosure of genetic information. This 
dissertation submits that due to the absence of adequate guidance on disclosure of genetic 
information, medical practitioners are reluctant to breach confidentiality. As a result of this 
reluctance, third parties may experience harm that could have been prevented, or at the very 
                                                          
179 ibid 28. 
180 ibid 3. 




least mitigated. Consequently, there is a need for comprehensive legislation that will be 
effective in practice. Accordingly, this dissertation provides recommendations (discussed in 





Biomedical Principles of Ethics and Ethics Theories 
 
6.1 Introduction 
Theories in any field of study always seem to guide us to one particular perspective. The use 
of multiple theories, however, allow us to open our mind to various possibilities, with the 
understanding that there is not always one correct answer. The development and application 
of the principles of biomedical ethics and ethical theories have assisted healthcare 
practitioners in deciding what the best course of action is when faced with an ethical 
dilemma. This chapter will focus on the ethical implications involved in genetic testing and 
the disclosure of genetic information. It is submitted that these ethical considerations must be 
taken into account in order to effectively regulate the involuntary disclosure of genetic 
information.      
 
6.2 The History and Development of Ethical Principles and Theories 
The Belmont Report as well as philosophers Thomas Beauchamp and James Childress have 
influenced and accordingly shaped the way, in which, ethical principles are defined in the 
contemporary medical world.182 After the Nuremberg trials, persons across the globe became 
aware of biomedical experiments that were conducted on human subjects in concentration 
camps, that is, the atrocities that were committed by doctors and scientists. The findings of 
the Nuremburg trials seemed to suggest that doctors needed a certain standard to aspire to and 
thus the Nuremberg Code was drafted. The ethical rules and principles contained in the code 
were insufficient to guide doctors in complex situations. As a result, in 1979, the National 
Commission for the Protection of Human Subjects of Biomedical and Behavioral Research 
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was charged with the task of developing basic ethical principles that should guide biomedical 
and behavioral research that involve human subjects.183  
This commission produced what has since become known as the Belmont Report. The 
Belmont Report stated that there are three basic principles that are particularly relevant to the 
ethics involved in the research of human subjects: the principles of respect for persons, 
beneficence and justice.184 On the other hand, however, writers Beauchamp and Childress 
proposed that there are four principles that are relevant to the ethics involving human 
subjects: autonomy, beneficence, non-maleficence and justice.185    
 
6.3 Ethical Theories 
Ethical theories act as a theoretical framework in which individuals, and in this instance 
healthcare professionals, use when faced with an ethical dilemma. An ethical theory provides 
a moral standard that may be used to assess what is morally right and wrong regarding the 
actions of a healthcare professional. There are several different competing theories that can  
be used by a healthcare practitioner to justify an action as ethical. This dissertation, however, 
will be focusing on three theories in particular, namely, utilitarianism, virtue ethics and 
narrative ethics.186 These particular theories were chosen in order to provide different 
perspectives as to what a medical professional ought to do and ought not to do. The 
application of these theories will demonstrate the benefits and limits of each approach taken 
by a clinician. It is hoped, that by using these specific theories, a clinician will find a 
balanced approach when facing a possible disclosure case.             
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Utilitarianism is said to be a form of the Consequential theories that focuses on the 
consequences of a decision.187 In 1776, philosopher Jeremy Bentham developed a 
fundamental maxim that would become synonymous with the notion of utilitarianism: 'it is 
the greatest happiness of the greatest number that is the measure of right and wrong'.188 In 
terms of Bentham's principle of utilitarianism, one must evaluate actions based on their 
consequences. From this, we can infer that Bentham's theory of utilitarianism means that one 
should perform the action that will bring about the best overall consequence by providing the 
greatest amount of happiness for the greatest number of people. 189       
Actions can be explained simplistically by stating that actions thought to produce good 
consequences are good actions, while actions thought to produce bad consequences are bad 
actions. In terms of a utilitarian approach, when faced with an ethical dilemma, the following 
must be done:190 
(i) An examination of the possible and likely short- and long-term consequences that are as a 
result of the decision/action.    
(ii) Consequences must be compared in order to determine how many people will be helped 
and to what degree, and how many harmed and to what degree.  
 According to utilitarianism, a clinician's decision to make the disclosure should be 
determined by the action that would provide the greatest amount of happiness. There are two 
options in this instance: keeping the confidentiality of their patient or making a disclosure to 
ensure the well-being of affected third parties. It is essential that we examine genetic 
information in a utilitarianism context as the patient is not the only individual that is affected 
by the results. In the instance where genetic testing reveals information that a patient's family 
are also at risk, a doctor's actions are of utmost importance. 
The confidentiality of a doctor-patient relationship is always at the forefront of a medical 
practitioner's decision making process. However, where there are affected related third 
parties, medical practitioners must also ensure that there is thought for the well-being of these 
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at-risk relatives. A medical practitioner must consider the number of affected relatives that 
they will be able to help. An early warning to the presence of a genetic condition can afford 
at-risk third parties an opportunity to seek out life saving treatment. Disclosure from a 
clinician will provide these at-risk third parties with time, giving them an opportunity to deal 
with the emotional and psychological strain associated with genetic conditions. It will also 
help them make informed decisions on the management and treatment of the condition.  
In certain circumstances, a medical practitioner has an opportunity to help an affected third 
party take preventative measures ensuring that the at-risk relative does not develop the 
genetic condition. It seems senseless for a medical practitioner to have access to potential life 
saving information, yet not share it due to the constraints of a doctor-patient relationship. To 
take the utilitarian perspective further, it is not just existing family members that may benefit 
from the information as genetic information may also reveal information regarding future 
offspring. Individuals would have knowledge that if they were to have children, their child 
might be born with or eventually develop a genetic disorder. In this instance, disclosure is the 
responsible decision as it prevents parents from undergoing the financial burden and 
emotional stress associated with having a child who has a genetic condition.  
Accordingly, a medical practitioner's decision or action to make the disclosure would cause 
the greatest amount of benefit for the greatest number of people and thus their action would 
be justified in terms of utilitarianism. At the same time, however, the utilitarianism approach 
in this instance may be criticized. Even though the involuntary disclosure of information will 
be beneficial to affected family members, when a doctor follows the utilitarianism theory, 
there is bound to be harm caused to others.191 In this instance, it is the patient that is harmed.  
The healthcare professional must keep in mind that once he or she breaches confidentiality, 
the patient, in all likelihood, will refuse to continue the doctor-patient relationship. Also, in 
the event that the patient seeks out other available healthcare practitioners, it is probable that 
the patient would continue their distrust for medical professionals. This distrust does not 
allow for an effective doctor-patient relationship, thus compromising patient care and 
treatment.  
Another criticism of utilitarianism is that the prediction of consequence are not an exact 
science, and this is certainly true in terms of genetic testing. As stated earlier, genetic testing 
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cannot always predict with certainty that an individual will, in fact, develop the genetic 
condition. Here, a medical practitioner is basing their decision to take a certain course of 
action in anticipation of a consequence that may never materialize,192 that is, the affected 
third parties may never develop the condition. In this instance, the harm caused to the doctor-
patient relationship would have been futile.      
 
6.3.2 Virtue Ethics             
Inspiration for virtue ethics has been taken from the declarations of Greek philosopher, 
Aristotle who stated that a virtuous individual is someone who is in possession of ideal 
character traits that are derived from natural internal tendencies.193 The main element that 
characterizes virtue ethics is an emphasis on the moral character of an agent and in this 
instance the healthcare practitioner. There has been much discussion as to how and why a 
healthcare professional should come to a decision when making a choice of whether or not to 
disclose information, but there has not been any explicit discussion on the healthcare 
practitioner himself.  
In terms of virtue ethics, there is an assumption that a healthcare practitioner will only make 
morally appropriate decisions if he or she is a morally sensitive and skilled person. Virtue 
ethics focuses on the education, background, experience and development of the specific 
healthcare professional making the decision. A healthcare practitioner will make a decision 
for their patient based on their past experience in the belief that the decision they are making 
is the right one. Virtue ethicists believe that in order for a morally virtuous person to make a 
ethically correct decision, they require a good motive and the skills and practice that come 
with experience.194                           
In South Africa, it appears that a medical practitioner is the only person who is required to 
make the decision of whether or not to disclose. It is apparent that there are no safeguards in 
place to ensure an objective and thorough decision making process. In terms of virtue ethics, 
the healthcare practitioner will use their past experience to come to a decision of whether or 
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not they should make the disclosure. It is disconcerting that practitioners are allowed to make 
a completely subjective decision with no thought of an objective standard. 
A known criticism of virtue ethics is that a good motive combined with knowledge and 
experience does not guarantee that a good decision will be made in each instance.195 
Although experts in the medical field, it is apparent that most medical professionals dealing 
with genetic testing do not have the required expertise that is needed to make such a complex 
decision. Accordingly, it is probable that a medical practitioner's lack of experience in this 
area will make it difficult for him or her to come to a virtuous decision in every case. 
Consequently, a major question that this study asks is whether such a decision should be 
made at the sole discretion of the medical practitioner involved. In answer to this question, it 
is important to emphasize that a healthcare practitioner's final decision may impact on more 
than just one person. As a result, this study recommends that a medical practitioner cannot be 
the only professional involved in making the decision. The decision to disclose must be done 
in consultation with others and with an objective standard in mind.  
 
6.3.3 Narrative Ethics                                  
The telling of a story has always been helpful in fleshing out a dilemma in medical ethics. 
Accordingly, by shining a light on the human perspective, we gain insight into a person's life 
and the complicated relationships they are apart off.196 Narrative ethics is essentially a patient 
centered approach that requires time and resources and is thus of particular relevance in terms 
of genetic testing. Narrative ethics may only be effective in private practices and considering 
that genetic testing in South Africa generally occurs in these practices, it is apparent that there 
is the need to examine and involve a narrative approach.    
Narrative ethics emphasizes a storytelling approach in which a patient's illness is the telling 
of a story that requires compassion and empathy. Allowing a patient an opportunity to outline 
their narrative provides the medical practitioner with a greater understanding of specific 
details of the case that is useful in the diagnostic process, details that the medical practitioner 
would not have known if not for the narrative of the patient. In order to assist the patient and 
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their family in coming to an appropriate course of action, a medical practitioner must 
understand, appreciate and be interested in the narrative of the patient.     
When a clinician decides to disclose private genetic information to affected parties, they do 
so in the belief that it is in the best interests of the third party. In other words, the medical 
practitioner's approach seems to be one sided, focused on the well-being of affected third 
parties. While such actions by medical practitioners may be considered as admirable, it 
cannot continue. A more balanced decision-making process must take place which requires 
the use of a narrative ethics approach. 
It is my submission that patients who refuse to consent to the disclosure should be given the 
opportunity to tell their story. Healthcare practitioners should allow patients to explain their 
decision as to why they do not wish for affected third parties to know that they are at risk. 
Since this dissertation is not advocating involuntary disclosure in every case, the reason as to 
why a patient refuses to consent, should play a pivotal role in the ultimate decision made by 
the healthcare professional. 
For example, the instance where a patient refuses to consent because he or she does not want 
family members to know of their condition can be deemed to be an insufficient reason. In this 
situation, a patient would claim that their genetic condition is private, but at the same time the 
medical practitioner must be aware that their patient's right to privacy may be limited. 
However, a medical practitioner may experience problems where a patient's refusal to 
consent is more virtuous, based on the well-being of related affected third parties. In this 
instance, a more thorough decision-making process is needed.   
 
6.3.3.1 Reasons to Refuse Consent  
A patient's reason for refusing consent is another concept at the core of this dissertation. 
Accordingly, it is important to discuss certain scenarios that might occur in real life which 
have been brought to the attention of a medical practitioner by the patient through a narrative 
ethics approach. The following are examples of reasons a patient may have to refuse consent:           
(i) The patient is of the belief that any disclosure would be unproductive as the condition is 
extremely serious or at such an advanced stage that medical intervention would not be able to 
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delay or alleviate the condition.197 For example, medical interventions and treatment options 
for Huntington disease are minimal and at present, are only at the beginning stages.198     
(ii) The patient is of the belief that if the related third party knew that he or she was going to 
develop the genetic condition, it would affect the third party's chances of obtaining life or 
health insurance at an affordable rate.199 
(iii) A patient may believe that if the related third party were to have knowledge of the 
genetic condition, then he or she would have a negative outlook on life, affecting their overall 
quality of life. In this instance, an individual would go through severe emotional and 
psychological trauma upon discovering that they have a life-altering or fatal genetic 
condition. At the same time, however, it must be noted that such a reason is not sufficiently 
adequate. When a person experiences sudden traumatic news, it is only natural to go through 
a period of adjustment. However, where a third party will be particularly sensitive to such 
news (e.g. third party is at an advanced age), a medical practitioner must take the particular 
circumstances under consideration.  
(iv) The patient believes that the related affected third party will not be able to afford medical 
treatment for the genetic condition. Disclosure in this instance would seem to be fruitless.  
(v) The patient believes that a third party, as a result of the disclosure, will limit their quality 
of life by choosing not to get married or have children. Such restrictive decision making on 
the part of the third party is bound to lead that third party to a life based on frustration and 
isolation.200 
(vi) A patient may also be concerned of becoming stigmatized by relatives who have 
knowledge of their condition. Essentially, a patient may be worried that they would be treated 
differently. In fact, a patient may even believe that family members may use such information 
for malicious purposes.201     
(vii) A patient could also be estranged from their family as a result of a serious falling out or 
even past abuse. In this instance, the patient would fear being traced through the disclosure.   
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6.4 Biomedical Principles 
6.4.1 Autonomy           
As we can see from the above, there may be instances where a patient has a valid reason for 
not consenting to the disclosure. The patient's right to self-determination should also be 
evaluated in a clinician's decision making process and thus the ethical principle of autonomy 
must be examined.  The literal meaning of autonomy is self-rule.202 In terms of this principle, 
a patient must be given the opportunity to make the ultimate decision regarding their 
treatment after a healthcare practitioner has provided him or her with all the relevant 
information.203 It is important for healthcare practitioners to respect autonomous individuals 
by giving weight to their considered opinions and choices, while abstaining from preventing 
or influencing their actions, unless these actions are detrimental to others. If a healthcare 
practitioner were to reject an autonomous individual’s considered judgement, it would 
indicate a clear lack of respect for such person.204  
Even though the patient may have the right to self-determination and thus the right to refuse 
the disclosure, it is important to remember that a third party may also feel as if they have a 
right to know of the existence of any genetic condition. The majority of related affected third 
parties would undoubtedly want to know if there is possibility that they may develop a 
genetic condition as such information would allow these individuals to make responsible and 
informed choices.205  
 
6.4.2 Justice 
The principle of justice deals with fairness in distribution. In terms of justice, if a person is 
denied a benefit they are entitled to without good reason, or if a burden is unduly imposed on 
a person, it is said that an injustice has occurred.206 Parker and Lucassen state that the 
principle of justice underpins their notion of the joint account model. According to this 
                                                          
202 K Moodley Medical Ethics, Law and Human Rights: a South African Perspective (2011) 42. 
203 ibid 42. 
204 J A Singh ‘Ethical Decision-making’ in MA Dada and DJ Mcquoid-Mason (eds.) Introduction to Medico-
Legal Practice (2001) 36. 
205 K G Fulda & K Lykens 'Ethical issues in predictive genetic testing: a public health perspective' (2006) 32 
Journal of Medical Ethics 145 
206 J A Singh ‘Ethical Decision-making’ in MA Dada and DJ Mcquoid-Mason (eds.) Introduction to Medico-
Legal Practice (2001) 37. 
57 
 
model, 'genetic information is shared by more than just one person'207 and should therefore be 
considered as familial in nature.208 Parker and Lucassen have reasoned that there is no 
rationale as to why only one person in that family should be able to receive the benefit and 
accordingly exclude other relatives from the same benefit.209 In this instance, the information 
will not be shared if the patient has a good reason to refuse consent.210 Writers have gone so 
far as to suggest that genetic information may be regarded as collective or shared 
information.211 Although this study advocates for the disclosure of genetic information to 
affected relatives, it is important to remember that disclosure can become a slippery slope for 
any healthcare practitioner. In this regard, clinicians should always be wary as it may be 
exceptionally easy to justify a case for disclosure of genetic information in every instance. A 
clinician should never forget the importance of confidentiality. 
 
6.4.3 Non-Maleficence and Beneficence 
At its very essence, non-maleficence prohibits healthcare practitioners from causing harm 
onto others.212 Beauchamp and Childress have provided certain rules in terms of the principle 
of non-maleficience. For example, a healthcare practitioner should refrain from inflicting 
pain and suffering onto a patient.213 It is interesting to note that harm is not restricted to 
physical harm alone as medical practitioners should also refrain from offending a patient and 
impeding their good quality of life.214 From this we can infer that Beauchamp and Childress 
have included mental and emotional harm in their examination of non-maleficence.   
Accordingly, it may be argued that the principle of non-maleficence is violated when a 
medical practitioner decides to make a disclosure against the wishes of their patient. In such a 
scenario, the decision to disclose could cause serious upheaval in a patient's life. Putting aside 
the harm done to the patient's emotional well-being, there is also the harm done to the doctor-
patient relationship. As discussed earlier, under the theory of utilitarianism, the medical 
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practitioner's actions will irreversibly damage the doctor-patient relationship, negatively 
impacting the treatment of the patient. From the above, it is ostensible that any disclosure on 
the part of a clinician would be a contravention of the principle of non-maleficence.   
Furthermore, there is the concept of beneficence which in essence is understood as acts of 
charity that go beyond a person's obligation.215 This terms encompasses the moral essence of 
obligations healthcare practitioners owe to their patients.216 Accordingly, beneficence is at the 
very core of the duty to warn. Essentially, even though a medical practitioner may not by law 
be required to make a disclosure to an affected related third party, he or she may feel they 
have a moral duty to that patient and thus the clinician performs an act of kindness by 
disclosing potentially life-saving genetic information.   
 
 
6.5 Organizational Ethics  
A medical practitioner should make every effort to ensure that access to the information is 
kept to a minimum by ensuring that those who are made aware of the information uphold its 
confidentiality. This is especially important in healthcare institutions and practices, where 
there is likely to be a breach of confidentiality, as certain persons (e.g. laboratory technicians) 
have access to a patient's confidential information.217   
This is one of the reasons why this study suggests that health establishments develop and 
implement organizational ethics policies. Organizational ethics are concerned with ethical 
issues that healthcare establishments are faced with. In terms of organizational ethics, 
managers and governors of health facilities attempt to identify areas where values conflict in 
order to find solutions to these problems. When attempting to find a resolution, an ethics 
approach is used in which decision-making is based on certain values. Also, ethics policies 
would allow for a different understanding than the legal definition of confidentiality.218  
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Whereas the law tells medical practitioners what they must do, ethics provides guidance by 
assisting a practitioner in determining what they should do. Where there is a conflict of 
interest, the ethical decision making process will assist in establishing the ethical legitimacy 
of decisions, demonstrating how decisions ought to be made. Overall, ethical policies and 
decision-making frameworks can be effective mechanisms for guiding ethical conduct in 
circumstances where interests tend to conflict.219         
Despite its effectiveness, it is important to remember that organizational ethics polices are 
still inferior to the law as well as professional guidelines. When ethics policies are 
implemented in healthcare facilities, it is highly improbable that they would be found legally 
binding. A violation of such a policy is likely to result in the individual being disciplined 
internally, instead of being liable in terms of the law. Accordingly, the ideal solution would 
be the development of legislation that will ensure repercussions for ethically ill-advised 
conduct in the context of involuntarily disclosure.      
 
6.6 Conclusion   
From the above discussion of ethics, it is apparent that there is still no clear cut answer as to 
how medical practitioners should conduct themselves during and after the genetic testing 
process. However, the discussion of different theories and principles have provided us with 
various perspectives that will assist us in developing adequate regulations for medical 
practitioners. Essentially, in practice, after an application of ethical principles and theories to 
the relevant circumstances, a medical practitioner must balance the different theories and 
principles in order to come to the best possible solution for all parties. An understanding of 
bioethics has helped us to comprehend that healthcare professionals actions cannot be one 




                                                          




Foreign and International Guidance on Confidentiality and 
Disclosure 
 
7.1 Introduction  
Medical practitioners throughout the world have been facing issues surrounding patient 
confidentiality and at-risk relatives. The complexities involved in the disclosure of genetic 
information have forced numerous countries into taking action in an attempt to regulate these 
complexities. This chapter traces the development of governance documents that have 
governed the disclosure of genetic information. It goes on to analyze and discuss current 
governance documents of certain foreign jurisdictions and international organizations that 
have been effective in governing this matter. Lastly, this chapter explores the scope of the 
duty to warn in terms of foreign law. 
 
7.2 The Development of Governance Documents  
In 1983, the United State's President's Commission for the Study of Ethical Problems in 
Medicine and Biomedical and Behavioral Research correctly anticipated that genetic 
technology would be greatly magnified in future decades.220 The commission concluded that 
confidentiality may be breached and genetic information may be disclosed to family members 
if the following conditions are met:221 
(i) A reasonable effort to obtain consent to the disclosure has failed; 
(ii) It is highly probable that the harm will materialize if the information is not disclosed. 
Also, the information that is withheld could be used to prevent the harm; 
(iii) The harm that the third party would suffer would constitute serious harm; and  
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(iv) There are adequate precautions taken to ensure that only the essential genetic information 
is disclosed.     
In 1994, the American Institute of Medicine Committee compiled a report that assessed 
genetic risks. The committee suggested an approach called the "Miranda Warning". In terms 
of the Miranda warning, a patient would be informed in advance of the circumstances that 
would warrant the disclosure of genetic information to at-risk family members. Under these 
circumstances, the patient's consent would not be needed.222 This approach is commendable 
in that it attempts to preserve the doctor-patient relationship.223 On the other hand, however, a 
patient might be reluctant to undergo the testing in the first place, for fear that family 
members might become aware of their results.                 
 
7.3 International Governance Documents  
7.3.1 World Health Organization  
The only form of guidance that the World Health Organization (WHO) has provided on this 
matter takes the form of a document titled Review of Ethical Issues in Medical Genetics.224 In 
terms of these guidelines, a clinician may inform affected persons if there is a likelihood of 
serious harm, despite the patient's wishes. Provided, however, that the following four 
conditions are met:225 
i) Every effort that has been made to persuade the patient to make the disclosure has failed. 
ii) If the relevant information is not disclosed, there is a high risk of harm to family members 
(including potential children). Also, there must be proof that the information could be used to 
prevent future harm. 
iii) The harm to affected persons is serious. 
iv) Only genetic information that is directly relevant to the affected party should be disclosed. 
Information that pertains to the individual must be kept confidential.    
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The document makes an impact by stating that if these conditions are met, clinicians should 
not be held liable if a disclosure is made.226 Also, the fact that these guidelines have proposed 
pre- and post-test genetic counselling is an aspect that must be commended.227 Overall, it is 
apparent that WHO has taken a concise and straightforward approach. It appears that WHO 
have produced guidelines that could be effective in balancing the rights of a patient and those 
of affected relatives.            
 
7.3.2 UNESCO International Declaration on Human Genetic Data  
The United Nations Educational, Scientific and Cultural Organization International 
Declaration228 makes reference to the term genetic data instead of genetic information.229 The 
Declaration affords genetic data a special status for several reasons. These reasons include the 
fact that genetic data can predict the genetic predispositions of individuals and that it may 
have a noticeable impact on family members, including potential children.230 Accordingly, 
we can infer that genetic data contains similar information as genetic information and thus we 
may examine the declaration in context of this dissertation.      
Article 14 of the Declaration deals with privacy and confidentiality. It essentially encourages 
countries to protect the confidentiality of genetic data of an individual and their family.231 
More importantly, however, Article 14 goes on to state that genetic data should not be 
disclosed to third parties, without the consent of a patient.232 The declaration clearly supports 
a patient's right to confidentiality, failing to take into consideration the well-being of affected 
related third parties. Although admirable, such a straight forward approach is not practical 
when trying to resolve a conflict that affects several individuals.    
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7.3.3 HUGO Ethics Committee  
The Human Genome Organisation (HUGO) Ethics Committee, in a statement on DNA 
Sampling: Control and Access, has stated that 'shared biological risks [of family members] 
create special interests and moral obligations with respect to access, storage and destruction 
that may occasionally outweigh individual wishes'.233 Although HUGO have not released 
express guidelines on the issue, from the above statement it is clear that they view disclosure 
as an acceptable course of action in certain circumstances.    
 
7.3.4 World Medical Association  
The WMA has made their stance on the topic known in the form of a statement on Genetics 
and Medicine.234 According to paragraph 12 of this statement, a clinician may make a 
disclosure to affected third parties, without the consent of a patient, where not disclosing the 
genetic information would result in 'direct and imminent threat to the life or health'235 of a 
third party. The WMA goes on to state that the clinician should generally discuss the situation 
with the patient first.236  
Furthermore, unlike other guidelines, the WMA takes disclosure further by stating that it is 
preferable for a clinician, where possible, to consult an ethics committee before disclosing 
results to affected third parties.237 This is an interesting provision as it doesn't allow for 
autonomous decision-making on the part of the physician. In fact, by consulting an ethics 
committee the physician, in all probability, is receiving the most well-balanced opinion in the 
matter. Despite the good intentions of this provision, it is crucial to criticize the practicalities 
of it. Continuously finding and accessing an ethics committee does not seem like a feasible 
option. However, what we can learn from these guidelines is that clinicians do not need to 
make the decision of whether or not to disclose by themselves. There is no reason as to why 
there cannot be an accessible an informed committee at a hospital or practice.               
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7.4 Regional Governance Documents   
7.4.1 The European Convention on Human Rights and Biomedicine 
Unfortunately, the European Convention on Human Rights and Biomedicine does not 
explicitly regulate the involuntary disclosure of genetic information. 238 Article 10 of the 
Convention on Human Rights and Biomedicine,239 however, discusses private life and the 
right to information. Article 10 (1) of the Convention states that 'Everyone has the right to 
respect for private life in relation to information about his or her health'.240 From this, we can 
deduce that the Convention advocates a patient's right to privacy. Furthermore, however, 
article 26 of the Convention states that rights may be restricted where it is necessary in the 
interest of public safety or for the protection of public health.241 Accordingly, the Convention 
does not provide an absolute right of privacy for a patient. It may be argued that this 
restriction may allow the disclosure of genetic information to affected parties.    
 
7.5 Professional Ethics Guidance Documents  
7.5.1 United Kingdom 
7.5.1.1 General Medical Council            
The UK General Medical Council242 has produced guidance on confidentiality for doctors 
who are registered with them. These guidelines state that when a patient refuses to consent to 
the disclosure, a doctor must balance their duty to take care of their patient with their duty to 
protect another person from serious harm. It goes on to state that if possible, a patient's 
identity should not be disclosed when informing others of the risk they are facing.243 
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Although, these guidelines allow for the discretion of a doctor, it fails to lay out specific 
guidelines that will assist them through the decision-making process.  
 
7.5.1.2 British Medical Association: Confidentiality and Disclosure of 
Health Information          
In terms of British Medical Association (BMA) guidelines, healthcare professionals should 
play a vital role in advising patients on the implications of genetic information that affect 
family members. The guidelines also state that clinicians should encourage patients to share 
information with affected persons.244 The guidelines go on to state that where a patient 
refuses to consent to the disclosure, a doctor should consider certain factors, such as:245 
(i) The seriousness of the genetic disorder; 
(ii) If informed, can affected relatives take appropriate action to protect themselves; 
(iii) The patient's reason for refusing to consent to the disclosure; and 
(iv) What is the degree of harm or benefit of sharing and withholding the information.     
If after a consideration of these factors, a clinician is of the opinion that the disclosure should 
be made, he or she must first discuss the reasons for making the disclosure with the patient.246 
BMA clearly provides adequate guidelines, taking into consideration a patient's right to 
confidentiality as well as an endangered third party's right to know. The only area that may be 
problematic is the lack of explanations. Guidelines should provide more fleshed out 
regulations that assist a doctor in deciding how much weight to place on various 
circumstances or factors.       
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7.5.1.3 English Case Law: The Duty to Warn 
A good example that may shed some light on the duty to warn occurs when a person tests 
positive for a mutation in the breast cancer gene. Essentially, if a woman was aware of the 
fact that she has the BRCA mutation, she would know that she has a higher risk of 
developing breast cancer or even ovarian cancer. With such knowledge, she would be able to 
take preventative measures. For example, a woman may have a mastectomy which is the 
removal of both breasts. Although extreme, a mastectomy has been known to reduce the risk 
of breast cancer by approximately 90%.247            
In cases like these, it is important to question whether or not a clinician has a duty to warn an 
affected related third party. The duty to warn may be understood as a clinician's legal 
obligation to inform a third party of any imminent risk posed to their health, irrespective of a 
patient's right to confidentiality.248 In terms of this duty, it is essential to question whether 
prevention measures may be taken if an individual is warned of their genetic predisposition. 
For the most part, it seems that the duty to warn has been recognized and developed in the 
courts of foreign countries. Accordingly, the ambit and extent of the duty to warn must be 
examined.      
In the UK, there have been no cases that have specifically dealt with the disclosure of genetic 
information to affected third parties. However, there have been English cases that have 
considered the duty to warn.  In the case of W v Egdell,249 Dr Egdell, a psychiatrist provided a 
report on W, a patient who had been detained at a secure hospital after being convicted of 
manslaughter. The assessment provided did not support the removal of the patient to a less 
secure facility. W eventually brought an action against Dr Egdell for breach of 
confidentiality. The court held that Dr Egdell did owe his patient a duty of confidentiality. 
However, the court went on to say that disclosure in the public interest overrode the duty of 
confidentiality between a doctor and their patient.250  
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In addition, the court identified the following three elements which a psychiatrist must 
consider when deciding whether or not to breach confidentiality:251 
i) Disclosure is needed to protect the public interest. 
ii) The risk must be real. 
iii) The risk must involve physical harm.    
Although this case involved a psychiatrist, we can still note that there is precedent in the 
English legal system for putting the duty to warn ahead of the right to confidentiality. 
Whether or not this approach will be taken in future cases in terms of disclosure of genetic 
information is yet to be seen. Of important note, however, is the development of the duty 
itself. It appears that English and foreign courts alike will continue to expand the scope of the 
duty to warn as it relates to the relevant situation.252 South Africa should be drawing on the 
development of the duty in foreign law in order to establish the parameters of the duty to 
warn in South Africa.          
 
7.5.2 United States  
7.5.2.1 American Medical Association 
The American Medical Association's Code of Medical Ethics253 emphasizes the need for 
communication by recommending pre and post-test counselling for patients. The Code takes 
a proactive approach whereby a clinician discusses with their patient whether or not 
biological relatives should participate in the genetic testing process.254 In essence, the code 
states that before a patient undergoes testing, a clinician should tell the patient the 
'circumstances under which they would expect patients to notify biological relatives of the 
availability of information related to risk of disease'.255 On a positive note, this governance 
document informs the patient of the possibility of disclosure before the tests are even 
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conducted. The Code goes further by stating that clinicians should support their patient by 
assisting a patient in their communication with their relatives.256 
Despite its proactive approach, the Code could become problematic as a result of its 
vagueness. Firstly, there does not appear to be a formal set of circumstances under which a 
clinician might expect disclosure. More importantly, however, is the proactive approach 
itself. Informing patients on the possibility of disclosure before the testing process begins 
could be unproductive. In fear of their confidentiality being breached, a patient may refuse to 
proceed with the test at all. Accordingly, the code should have provided clinicians with more 
detailed guidelines on this matter. For example, would the refusal to consent to the disclosure 
during the pre-test counselling mean that the clinician would refuse to conduct the genetic 
tests in question? Guidelines of this nature should answer such questions and hence this study 
finds that this Code, despite its promise, has a long way to go.          
 
7.5.2.2 American Case Law: The Duty to Warn 
An example of an endangered third party can be seen in the American case of Tarasoff v 
Regents of the University of California.257 In this case, a male student told the university 
psychologist that he wanted to kill a female student, who had previously rejected his 
advances. The psychologist warned security services, but failed to inform the female student 
or her family. The male student eventually killed her and accordingly, the girl's family sued 
the University of California on the basis that the psychologist should have disclosed the threat 
to the girl so that she could have taken steps to protect herself. 258 
In the case, the defendant argued that the imposition placed on therapists to protect third 
parties was inconceivable as a therapist cannot adequately determine if a patient will in fact 
resort to violence.259 This argument can be countered by this study as where there is 
involuntary disclosure of genetic information, in most cases, a medical practitioner will be 
able to predict the harm that the third party will experience. However, problems may arise 
where there is just the chance that someone might develop a genetic condition. Although the 
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test does not provide absolute certainty in certain cases, the third party could pay the price 
when a doctor refuses to breach confidentiality.  
The court in Tarasoff used the example of a therapist failing to warn the authorities that his 
patient had threatened to assassinate the President, because the therapist could not 
conclusively predict that the patient would in fact commit the crime.260 Overall, the court 
realized the difficulty of predicting possible danger and thus stated that a therapist need only 
exercise 'that reasonable degree of skill, knowledge, and care ordinarily possessed and 
exercised by members of that professional specialty under similar circumstances'.261This 
study supports the approach taken in this case. Accordingly, it is submitted that this standard 
should be applied when a clinician is going through the decision making process.        
 The court stated that when a therapist establishes that their patient is a serious threat to 
another, a duty is placed on a therapist to take reasonable care to protect a third party from 
danger. The court went on to say that a therapist is required to take appropriate steps, 
depending on the circumstances of the case, in order to carry out their duty to warn. 
Furthermore, the court held that a therapist has an obligation to maintain the confidence of 
their patient, except where disclosure is necessary to prevent danger to others. In this 
instance, disclosure must be done in a manner that upholds the privacy of the patient. The 
court held that the university had a duty to warn the endangered third party and that 
'protective privilege ends where the public peril begins'.262 This is of particular relevance to 
the study. Essentially, when a medical professional decides to make a disclosure, he or she 
must do so by only sharing information relevant to the affected party. Any other information, 
including the identity of the patient (if possible), should remain confidential.  
Although this decision is not binding in South Africa, the Tarasoff judgment clearly has 
persuasive value throughout the world. This case attempts to define the parameters of 
confidentiality in a doctor-patient relationship. From the case, we can infer that the duty of 
confidentiality is inferior when put up against the well-being of an endangered third party. 
Even though this case deals with confidentiality in the context of a doctor-patient 
relationship, in which the doctor is a therapist, there is no reason as to why the principles that 
flow from this case cannot be used in a conventional doctor-patient relationship. It is 
submitted that this case can and should apply to the involuntary disclosure of genetic 
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information. The confidentiality of a doctor-patient relationship needs to stop when a third 
party can be helped by the disclosure of genetic information.  
On the other hand, however, it has been stated that genetic cases differ from cases involving a 
therapist. This aspect is worth examining as in genetic cases, the harm, to some extent, has 
already occurred as the affected third party would already have the gene mutation. 
Accordingly, no act on the part of the clinician can prevent the gene mutation from being 
present.263 What must be remembered, however, is that there is always the possibility of 
preventative measures. For this reason, disclosure must be given serious consideration in 
most cases.      
Another case of note is the 1995 American case of Pate v Threlkel.264 In this case, Heidi Pate 
sued her mother's medical practitioner for failing to warn her mother that thyroid cancer 
could be hereditary. She claimed that if her mother had been informed, she could have 
prevented her own condition. The Supreme Court of Florida agreed with Pate in that the 
physician has a duty to warn the patient about the hereditary nature of the condition. 265 
In 1996, however, the court in Safer v Estate of Pack266 broadened the duty to warn. In the 
case, Donna Safer sued the estate of the late Dr Pack who had treated her father for colorectal 
cancer. Donna Safer had eventually been diagnosed with colorectal cancer and claimed that 
Dr Pack had failed to warn those at risk. Contrary to Pate v Threlkel, the court stated that a 
doctor's duty to warn at-risk relatives may not always be met by informing the patient of the 
hereditary nature of the condition. The court held further, that a clinician must take 
reasonable steps to ensure that the immediate family members of the patient are warned.267 
This study supports the approach taken by this court. Where possible, a clinician should be 
taking reasonable steps to warn affected related third parties.      
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7.6 National Governance Documents  
7.6.1 Australia  
In 2006, Australia brought into operation the Privacy Legislation Amendment Act.268 The 
amended Act allows a healthcare professional to disclose genetic information to affected 
related third parties 'where there is reasonable belief that doing so is necessary to lessen or 
prevent a serious threat to the life, health or safety'269 of the third party. An important aspect 
of this amendment is that it is not necessary for the threat to be imminent.270  
The amendments made provide a framework to allow for the disclosure of genetic 
information in the appropriate circumstances, rather than simply placing an obligation on 
healthcare practitioners to disclose information in all instances. It is also praiseworthy that the 
amendment introduced the requirement for the National Health and Medical Research 
Council (NHMRC) to develop these guidelines, for healthcare practitioners in the private 
sector. This requirement allowed the NHMRC to take into consideration ethical matters and 
accordingly contribute guidelines and practical guidance that will supplement the 
amendment. However, a glaring shortfall of these guidelines is that they do not regulate 
genetic information that reveals a serious threat to unborn children.271 Also, it is important to 
keep in mind that these are not law, but rather non-binding guidelines.          
Taking into consideration the wording of the amendment, the guidelines have established a 
framework that dictates when, by whom and in what manner the disclosure of the information 
may occur, without a patient's consent. There is also a test. The test provides for disclosure 
where there is:272 
(i) a serious threat to life, health or safety of a genetic relative        
(ii) the use or disclosure is necessary to lessen or prevent the threat.  
When the above test is satisfied, a healthcare practitioner may disclose genetic information 
only where the disclosure is done in accordance with the guidelines. This study will only 
                                                          
268 Privacy Legislation Amendment Act 2006 (No. 99, 2006). 
269 National Health and Medical Research Council: Guidelines for health practitioners in the private sector 
(2009) 1. 
270 Privacy Legislation Amendment Act 2006 (No. 99, 2006) Schedule 2. 
271 National Health and Medical Research Council: Guidelines for health practitioners in the private sector 
(2009) 1-2. 
272 ibid 8. 
72 
 
discuss the guidelines of most relevance. Guideline 1 states that when determining whether 
there is a serious threat, the healthcare practitioner should consider two factors. Firstly, what 
is the nature of the condition and what are the risks and treatment options associated with the 
condition. Secondly, what are the chances that a genetic family member will also have or 
develop the genetic disorder or be a carrier of the relevant gene mutation.273   
Furthermore, if a medical practitioner concludes that there is, in fact, a serious threat, the 
practitioner should go on to determine if there is a possibility to lessen or prevent the threat. 
Here, a practitioner will consider whether the at-risk relative will be able to treat or prevent 
the condition if they had knowledge of the genetic condition. Also, if there is no cure for the 
disorder, will knowledge of the disorder assist a relative in managing the condition?274     
Guideline 2 discusses relevant ethical considerations that a healthcare practitioner should take 
into account when deciding whether or not to disclose. The guidelines state that effective 
communication between a practitioner and a patient at the initial consultation  may assist the 
patient in understanding the implications that may arise in genetic testing. Also, where a 
practitioner uses active listening techniques, he or she can fully understand the reasoning 
behind a patient's refusal to consent.275  
The guidelines discuss communication in two instances. Firstly, there should be genetic 
counselling.276 In this instance, however, the guidelines fail to make genetic counselling a 
compulsory undertaking for patients undergoing genetic testing. The second form of 
communication occurs where genetic tests confirm a genetic disorder or that there is a risk of 
a genetic disorder. In this situation, the practitioner should also discuss the implications for 
relatives with the patient. There should also be a discussion on the possible benefits of 
disclosing the information to affected relatives.277 However, such a regulation may be 
problematic. Consequently, it is submitted that such a discussion should occur during genetic 
counselling, before genetic tests are conducted.          
Guideline 3 states that a practitioner should first take reasonable steps to obtain the consent of 
the patient. According to this guideline, a patient should be given the necessary information 
in order to come to an informed decision. The guidelines provide a comprehensive list of 
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what the information should include, for example, which relatives are at risk and what is the 
likelihood of that relative developing the genetic condition.278        
 
7.7 Conclusion   
An analysis of the above governance documents has shown that the majority of foreign 
jurisdictions seem inclined to maintain confidentiality. However, they are also of the opinion 
that confidentiality is not absolute, and thus disclosure should be allowed in instances where 
the harm to an affected party is serious. Overall, from the detailed nature of guidance 
provided, it is clear that a considerable amount of understanding and expertise has gone into 
the development of the above documents. Presumably, these countries have experienced the 
same difficulties with disclosure as South Africa and thus an opportunity to learn from such 
documents should not be overlooked.  
Foreign guidelines seem to have understood the flexibility that is required when dealing with 
disclosure cases. For instance, Australian guidelines allow a medical practitioner to make a 
decision based on the facts and circumstances of each individual case. WHO has also 
produced guidelines that allow the clinician to view the circumstances from each individual's 
perspective. Accordingly, the main lesson that South Africa can learn from these guidelines 
lies in the fact that the above governance documents are by no means straightforward 
guidelines. South Africa must realize that there is no one course of action that will satisfy all 
circumstances. Any legislation created by South Africa in the future must account for the 
difficulties experienced by all parties involved, rather than just the patient. In particular, it is 
important for future legislation to recognise that affected related third parties may only 
receive treatment or manage the condition when they become aware that they may, in fact, 




                                                          







After an in depth analysis of South African law and ethics that surround the involuntary 
disclosure of genetic information, it is submitted that there is a need for Parliament to develop 
and implement legislation that regulates the confidentiality and disclosure of genetic 
information. This study wishes to propose recommendations that will assist health officials in 
developing informed legislation on genetics. The following recommendations are some of the 
essential matters that such legislation should contain. These recommendations attempt to 
balance a patient's right to privacy with an affected relative's right to know.  
 
8.2 Recommendations  
8.2.1 Genetic Information      
The statute should include a comprehensive and clear definition of genetic information. The 
following definition is recommended: 
Genetic information is information that is obtained as a result of:  
(i) an individual's genetic tests; 
(ii) the genetic tests of a genetic relative of the individual; 
(iii) pre-natal screening of the foetus; 
(iv) newborn screening of neonates; 
(v) pre-implantation testing of an embryo; 




(vii) any other genetic services or genetic research that a family member or the individual has 
participated in.  
Genetic information will exclude any information that is referred to as personal 
information.279     
 
8.2.2 Pre-test Counselling  
Pre-test counselling is essential in order to ensure that a patient fully grasps the complexities 
involved in genetic testing. It is recommended that only a genetic counsellor or a psychiatrist 
specializing in the complexities of genetic testing be responsible for conducting the pre-test 
counselling. The following should be discussed during pre-test counselling: 
 A patient's family history should be conducted in order to recognize or establish the 
inheritance pattern of the genetic condition.280  
 What can be learnt and observed from positive or negative genetic test results.281  
 A discussion on the manner in which the test will be conducted and accordingly the 
accuracy of such tests which includes an explanation of the reliability, limitations and 
uncertainty of the test.282  
 The genetic conditions that the individual is being tested for. In this explanation, there 
should be a discussion in which the patient understands the condition being tested for and 
the possible advantages of early detection. 
 The possibility of the genetic tests producing information that is relevant to the patient's 
family members.283 This situation occurs where the results may show that a relative of the 
patient will develop or is at risk of developing a genetic condition.       
 The confidentiality of genetic information. 
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 The possibility of disclosure to affected related third parties and how and by whom such a 
decision to disclose is made. It is important to discuss with the patient the possibility that 
disclosure to affected persons may be necessary. Having this discussion before the testing 
process promotes trust and honesty between counsellor and patient. The patient also has a 
chance to get used to the idea of disclosure to affected persons.      
 Lastly, the emotional and psychological state of the patient prior to the testing. 
Genetic pre-test counselling, however, should also afford a patient an opportunity to discuss 
their fears and reasons for non-disclosure to affected family members. Genetic counselling 
should be used to inform a patient that the genetic testing procedure is not just an individual 
process.284 At the same time, however, the purpose of pre-test counselling is not to obtain 
consent for the disclosure of genetic information.  
It is important that healthcare professionals do not decline to perform genetic tests on 
individuals who refuse to consent to disclosure. Such treatment cannot possibly be in the best 
interests of the patient. It seems harsh and to some extent senseless to obtain a patient's 
consent to disclose information that has not even being obtained yet. Accordingly, during the 
pre-test counselling, the psychiatrist should only make a patient aware that there is a 
possibility that their confidentiality may be breached.  
 
8.2.3 Post-test Counselling  
Once a patient is given the results of their genetic tests, there are several important decisions 
that must now be made. In post-test counselling, it is recommended that the same genetic 
counsellor or psychiatrist who conducted the pre-test counselling should be used as there is 
already a rapport established with the patient. With the presence of a medical practitioner, the 
following issues should be discussed in post-test counselling: 
 The emotional well-being of the patient in the event that the patient does have a genetic 
condition.285  
 Detailed information on the specific genetic condition.286 
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  Possible prevention, treatment or management options for the genetic condition.287 This 
discussion should include possible support mechanisms that will assist a patient in coping 
with the condition. 
 The risk of having a child with the particular condition should be evaluated and 
explained.288 
 Also, where a test reveals information on relatives, the healthcare professional should 
discuss the importance of disclosing such results to affected related third parties. This 
discussion should include the benefits and drawbacks of disclosing the information.289 
When genetic test results are obtained, a patient should be asked to consent to the disclosure 
of relevant genetic information to affected related third parties. During counselling, a patient 
should be encouraged to disclose the information. Where a patient refuses to consent, he or 
she should be informed that the confidential doctor-patient relationship is not automatically 
breached. It is the recommendation of this study that various factors should be considered, by 
a selected panel, before the decision to disclose is made. 
 
8.2.4 Who is to make the decision?             
It is the view of this study that a decision of whether or not to disclose cannot be made by a 
medical practitioner alone. This study recommends that the decision must be made by a select 
and informed panel. The panel should consist of a medical practitioner (preferably 
specializing in genetics), a psychiatrist specializing in human genetics and a genetic 
counsellor or social worker.  
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8.2.5 Factors to consider when making the decision to disclose involuntarily   
Before a panel decides whether or not genetic information should be disclosed to affected 
relatives, the following factors should be taken into consideration: 
a) The degree of accuracy of the information that has been provided by the genetic test. 
Where the results are uncertain, in that, it states that there is only a risk of the person 
developing the condition, the panel should use reasonable skill and experience in coming to a 
decision. In this instance, the panel should have a reasonable conviction that the affected 
relative would in fact develop the condition. The panel should also consider whether or not 
the relative will be a carrier for the genetic condition.290        
b) The severity of the genetic condition. In other words, does the genetic condition pose a 
serious threat to the health and safety of the individual. 291 Essentially, a medical professional 
must disclose pertinent genetic information to affected related parties where the harm of non-
disclosure outweighs the harm of disclosure.292 
c) Would the sharing of genetic information reduce the threat? Essentially, if the affected 
related third party has knowledge of the test results, is there an action that he or she could 
take to prevent the manifestation of the genetic condition. Also, is there effective treatment 
available for the genetic condition that would help the affected individual.293  
d) The patient's reason for refusing to consent to the disclosure.294   
e) Is the disclosure worth infringing a patient's right to privacy? The panel must consider the 
consequences of breaching confidentiality as the doctor-patient relationship could suffer 
irreparable harm. The disclosure could also create animosity between the patient and the 
affected relative.295     
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After a consideration of the above factors, if the panel believes that a disclosure to an affected 
related third party is justified, then the genetic information should be disclosed despite the 
lack of consent from the patient.  
 
8.2.6 Further Recommendations 
There are also general recommendations that need to be considered. Firstly, when a panel 
decides to make a disclosure, the panel should first inform the patient of their decision and 
the reasons as to why such a decision was made. Also, when a disclosure is made, if possible, 
the identity of the patient as well as the exact nature of their genetic condition should be kept 
confidential. Only relevant information should be disclosed.    
 
8.3 Conclusion               
At present, it is clear that South Africa's regulatory framework on the disclosure of genetic 
information is unsatisfactory. In order to deal with these challenges, this study has 
recommended comprehensive genetic privacy legislation. The above recommendations have 
been informed by governance documents of foreign jurisdictions as well as the basic 







The completion of the Human Genome Project has made scientists aware of the potential in 
the field of genetics. However, there is no denying that the current era of genetics imposes its 
own challenges to ethical and legal frameworks. The main area of law that seems to be tested 
in terms of genetics is the principle of confidentiality. Every patient walks into a clinician's 
office with the expectation that all health information will remain private. The value of 
confidentiality in the doctor-patient relationship is invaluable as it is essential to the treatment 
process. However, despite its importance, information of this nature cannot always remain 
confidential.   
As a result, the involuntary disclosure of genetic information is a problem that is bound to 
become more prevalent in South Africa. Foreseeing the possible difficulty health 
professionals will experience in the coming years, this dissertation has questioned the 
adequacy of current South African regulations regarding genetic information. After an in 
depth examination of existing guidelines, it is apparent that regulations do, in fact, cover 
certain issues. Overall, however, this study has concluded that these regulations are not 
satisfactory in that there are still gaps in our law that needs to be addressed. Accordingly, this 
dissertation sets out to provide ethically informed legislation and organizational ethics 
policies that fill in those gaps. 
Accordingly, the role of ethics policies should not be undervalued. The enactment of 
legislation is a lengthy process and thus there is a need for healthcare establishments, dealing 
with genetic testing, to develop their own institutional policies that regulate disclosure. Each 
individual health facility should establish ethical policies that are in sync with the values of 
the establishment. Those responsible for the governance of the health establishments will be 
able to produce policies that guide a clinician as to what they should do, rather than what they 
must do. 
Overall, genetic information in clinical settings tend to raise several ethical and legal 
concerns and although genetic testing is focused primarily on the private sector, these 
concerns should not go unnoticed. Foreign jurisdictions have already attempted to address 
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these complexities by putting into operation regulatory frameworks and guidelines that will 
mitigate ethical and legal concerns.  
In summary, it is submitted that the regulations put forward by South Africa have failed to 
address the concerns examined in this study. The failure to adequately define the duty of a 
medical practitioner has placed patients in uncomfortable positions and third parties at risk.  
Accordingly, it is submitted that the only way to effectively balance a patient's right to 
confidentiality and an endangered third party's right to know, is to develop legislation that 
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